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GENERAL INTRODUCTION
The idiopathic inflammatory myopathies (IIMs) also known as myositis, encompasses 
a spectrum of different clinical phenotypes with almost all having chronic muscle 
inflammation as hallmark. The inflammation frequently affects others organs, such as 
the skin, joints, lungs, gastro-intestinal tract and heart indicating the systemic nature 
of this disease. Different subgroups have been identified based on muscle and skin 
involvement and muscle biopsy findings, including polymyositis (PM), dermatomyositis 
(DM), inclusion body myositis (IBM), nonspecific myositis (NSM) and immune-mediated 
necrotizing myopathy (IMNM) (1). Although the exact pathogenesis remains unknown, 
there is convincing evidence for an immune-mediated disease mechanism considering 
the presence of mononuclear cell infiltrates found in muscle biopsies and response on 
immunosuppressive treatment. Furthermore, myositis specific autoantibodies (MSAs) are 
found in 60-70% of the patients with IIMs (2)
History	of	classification	of	IIMs
First reports of patients with dermatomyositis (DM) and polymyositis (PM) were 
described by Ernst Leberecht Wagner and Heinrich Unverricht in the late 19th century (3). 
They described independently of each other, three patients with acute muscle weakness in 
combination with skin lesions. Both authors called the disease polymyositis and it was also 
known as the Unverricht-Wagner of Wagner-Unverricht syndrome. Later on Unverricht 
changed the name of the disease to dermatomyositis. In 1916 Stertz was the first to 
publish about the association between dermatomyositis and malignancy (4). 
Table 1 | Bohan & Peter diagnostic and classification criteria for IIMs (7, 8)
1	 	Progressive	(over	weeks	to	months),	symmetrical	limb-girlde	and	anterior	neck	flexor	muscle	
weakness
2	 	Muscle	biopsy	evidence	of	necrosis,	phagocytosis,	regeneration,	perifascular	atrophy	and	an	
inflammatory	exsudate
3	 Increased	serum	creatine	kinase
4	 	Electromyographic	evidence	of	myopathic	motor	units,	fibrillations,	positive	sharp	waves,	in-
creased insertional irritability
5	 	Dermatological	features:	lilac	discoloration	eyelids,	Gottron’s	sign	and	erythematous	dermatitis	
of	knees,	elbows,	upper	part	torso,	face	and	neck
 
Exclusion	criteria:	a	slow	progressive	course,	a	positive	family	history	to	rule	out	muscular	dystrophies	
and	many	other	neuromuscular	disorders
Definite	PM:	requires	the	inclusion	criteria	1-4	and	a	diagnosis	of	definite	DM	is	made	if	typical	skin	
lesions	are	present	in	addition	to	at	least	3	of	the	other	criteria	
 
Medsger et al. and DeVere and Bradley developed the first set of modern criteria for IIM 
in the 1970s (5, 6). In 1975 Bohan and Peter published the currently most used diagnostic/
classification criteria for IIM (see Table 1) (7, 8). Bohan and Peter suggested a subclassification 
into five subgroups: PM, DM, juvenile PM or DM, overlap myositis (defined as myositis in 
presence of other rheumatological diagnosis) and myositis associated with malignancy. 
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According to these criteria skin abnormalities were the only distinction between DM and 
PM. A main limitation of these criteria was the lack of inclusion body myositis (IBM) as a 
subgroup. 
In 1995, Tanimoto et al. developed new classification criteria for PM and DM which were 
based on the Bohan and Peter criteria (9). These new criteria added items as myalgia, non-
erosive arthritis, fever and for the first time myositis-specific autoantibodies (MSAs) (Jo1 
autoantibodies). In addition Targoff et al. included in 1997 new MSAs (autoantibodies 
against aminoacyl transfer RNA synthetases (ARSs), signal recognition particle (SRP) 
or Mi2 autoantigens) (10). The inclusion of these MSAs in these criteria underline the 
growing acknowledgement that MSA are helpful in stratifying patients into different 
clinical phenotypes. Furthermore, Targoff added MRI findings in the classification criteria 
by which MRI-determined inflammation of skeletal muscle could substitute for clinical 
muscle weakness or elevated muscle enzyme in sera. 
In 2005, Troyanov et al. proposed new classification criteria, with main improvement 
for overlap myositis by inclusion of serological markers (11). Overlap myositis was 
defined by the presence of myositis and at least one clinical overlap feature and/or an 
overlap autoantibody, including the anti-ARS autoantibodies (commonly referred to as 
antisynthetase antibodies), anti-SRP antibodies, systemic sclerosis-associated antibodies 
(antibodies to centromeres, topoisomerase I, Th/To autoantigens, RNA polymerase I or III, 
Pm/Scl, U1 ribonucleoprotein or Ku protein), as well as antibodies against nucleoporins. 
This classification system lead to a better subclassification of PM. Better subclassification 
leads to better identification of the different overlap myositis patients. Limited is known 
about organ involvement, histopathology or survival of these patients with overlap 
myositis. Thus, there is need to improve knowledge regarding these clinical aspects of 
patients with overlap myositis to possibly improve treatment and survival. 
In 2004 an international multidisciplinary joined effort was started to develop new 
classification for IIM, which were finalized in 2017. The long development period was 
needed to recruit sufficient cases for these criteria and validation (12). The project was 
supported by expert in the field of IIM from the EULAR, ACR and the International 
Myositis Assessment and Clinical Studies Group (IMACS) leading to the publication of 
the new classification criteria for IIMs in 2017 (12). A novel probability score model was 
developed to distinguish patients with IIM from patients with no IIM. The model includes 
16 variables and each variable provides a score based on the predictive ability (see Table 
2). The sum of the scores provides a probability of having IIM (probable/definite). A tree 
classification approach was used for identifying subgroups of IIMs such as patients with 
juvenile or adult dermatomyositis, amyopathic dermatomyositis, IBM or subgroups within 
polymyositis. This new criteria has several advantages such as the provided individual 
weights of each item meaning that one needs to test only enough variables to reach a 
predefined probability of having IIM. Secondly, the model provides two sets of scoring, 
with or without muscle biopsy. Thirdly, these criteria are validated in a external cohort 
13
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which is often lacking in previously proposed criteria. Limitations of the new criteria are 
that no imaging items such as MRI or muscle ultrasound were added. In addition, not all 
known MSAs were added in the criteria. This can partly be explained by the fact that during 
the development of these criteria new MSAs were identified for example as the anti-cN-1A 
and anti-HMGCR autoantibodies. In conclusion, the latest and new EULAR-ACR criteria 
for adult and juvenile IIMs and their major subgroups are a considerable improvement to 
capture the different phenotypes of IIMs leading to better understanding of pathogenesis, 
prognosis and further tailoring of treatment. 
 
Figure 1 | Development of classification criteria of IIMs over time, adapted from Lundberg et al. (13)
The	first	set	of	modern	
diagnostic	criteria	for	
myositis (Medsger criteria)8
Love	et	al.	put	forward	a	new
approach	for	the	classification
of	IIMs,	on	the	basis	of	MSAs4
Dalakas	proposes	classification
criteria	for	PM,	DM	and	IBM65
Bohan	and	Peter	criteria
for	the	diagnosis	of	PM
and DM10,11
DeVere	and	Bradley
criteria	for	PM9
ENMC	proposes	two	new	entities	
within	the	PM	spectrum:	IMNM	
and	nonspecific	myositis2
Troyanov	et	al.	propose	a
classification	system	on	the	basis
of	clinical–serological	definitions,
introducing	the	subgroup
clinicoserologic	overlap	myositis15
Dalakas	and	Hohlfeld	put
forward	distinguishing
unique	histological	features
of	DM,	PM	and	IBM1
Pestronk	proposes	
classification	criteria	
for	IIM	on	the	basis	of	
histopathological	features66
EULAR–ACR	classification
criteria	for	adult	and
juvenile	IIMs	and	their
major	subgroups6,7
Targoff	et	al.
classification
criteria	for	IIMs14
IIM	criteria																		Specific	criteria	for	IBM
ENMC diagnostic
criteria	for	IBM48
Griggs et al. diagnostic
criteria	for	IBM45
Tanimoto et al.
classification	criteria
for	PM	and	DM13
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Table 2 | The EULAR–ACR classification criteria for adult and juvenile IIMs and their major 
subgroups 6,7
Epidemiology
IIMs are rare diseases and have been described in all races. The reported combined annual 
incidence of polymyositis (PM) and dermatomyositis (DM) varies from 0.7 to 2 per 105 in 
the general population (14-18). Women are up to a twofold more often affected and the peak 
of onset occurs after the age of 40 (18-20). The reported estimates of prevalence vary from 
7.2 per 105 in Argentina, 13.2 per 105 in Japan and 14 per 105 in Sweden (17, 18, 21).
Muscle biopsy available
•		Probable	idiopathic	inflammatory	myopathies	(IIMs):	aggregated	score	(probability	≥55%	and	<90%)	≥6.7	and	<8.7
•	Definite	IIMs:	aggregated	score	(probability	≥90%)	≥8.7
Muscle biopsy not available
•	Probable	IIMs:	aggregated	score	(probability	≥55%	and	<90%)	≥5.5	and	<7.5
•	Definite	IIMs:	aggregated	score	(≥90%	probability)	≥7
Variable Score
Without	
muscle	biopsy
With 
muscle	biopsy
Age	of	onset	of	first	symptom	assumed	to	be	related	to	the	disease	≥18	years	and	<	40	
years
1.3 1.5
Age	of	onset	of	first	symptom	assumed	to	be	related	to	the	disease	≥40	years 2.1 2.2
Muscle weakness
Objective	symmetrical	weakness,	usually	progressive,	of	the	proximal	upper	extremities 0.7 0.7
Objective	symmetrical	weakness,	usually	progressive,	of	the	proximal	lower	extremities 0.8 0.5
Neck	flexors	are	relatively	weaker	than	neck	extensors 1.9 1.6
In	the	legs,	proximal	muscles	are	relatively	weaker	than	distal	muscles 0.9 1.2
Skin manifestations
Heliotrope	rash 3.1 3.2
Gottron	papules 2.1 2.7
Gottron sign 3.3 3.7
Other clinical manifestations
Dysphagia	or	oesophageal	dysmotility 0.7 0.6
Laboratory measurements
Anti-histidyl-transfer	RNA	synthetase	(Jo1)	autoantibody	present 3.9 3.8
Elevated	serum	levels	of	one	of	the	following	enzymesa:	creatine	kinase,	lactate	dehydro-
genase,	aspartate	aminotransferase	or	alanine	aminotransferase
1.3 1.4
Muscle biopsy features — presence of
Endomysial	infiltration	of	mononuclear	cells	surrounding,	but	not	invading,	myofibres –	 1.7
Perimysial	and/or	perivascular	infiltration	of	mononuclear	cells	 –	 1.2
Perifascicular	atrophy	 –	 1.9
Rimmed	vacuoles	 –	 3.1
Table adapted from Lundberg, I. E. et al. 2017 European League Against Rheumatism/American College of Rheumatology 
classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 76, 
1955–1964 (2017) (REF. 6) and with permission from REF. 7, Wiley. 
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Diagnosis
In the past 20 years, the knowledge on IIM has increased also due to more international 
collaboration. These collaborations resulted in the ACR EULAR classification criteria for 
IIM. In daily clinical practice, diagnosing IIM is challenging. The treating physician will 
initiate tests for IIM in patients with typical symptoms, and those tests generally consist of 
EMG and muscle biopsy. However, these are both invasive and possible painful procedures. 
There is unmet need for non-invasive diagnostic tools in IIM. Candidates as non-invasive 
tools are muscle ultrasound and MRI.
Muscle ultrasound
Imaging plays an important role in the assessment of myopathies by screening for 
presence, severity or activity of the disease (22). Although MRI has been considered the 
gold standard imaging modality for IIM, it can be expensive, time-consuming, and difficult 
to obtain in patients with implants or children (23). During the last years muscle ultrasound 
has become an important tool for evaluation in neuromuscular diseases (24-26). Furthermore, 
Quantitative muscle ultrasound (QMUS) imaging has proven to be a useful, non-invasive 
technique to visualize pathological skeletal muscle tissue among patients with IIM (24, 
25, 27-32). Visual detection of slightly increased muscle echo intensity can be difficult and 
greatly depends on the experience of the observer. Therefore, visual evaluation of muscle 
ultrasound revealed a relative low interobserver agreement (kappa = 0.53), which further 
deteriorated when an inexperienced observer interpreted the images (33). As a consequence 
computer-aided techniques have been introduced in image interpretation. This led to an 
objective quantification of muscle echo intensity (QMUS) with gray-scale analysis. This 
step forward with QMUS lead to an improved interobserver agreement (kappa = 0.86) and 
possibility for comparison in research settings (33). Previous studies suggest that active 
myositis during diagnosis is accompanied by a relative low echointensity and normal 
muscle size or slight swelling due to muscle edema (30, 34). In contrary, previous results of 
our research efforts in patients with juvenile dermatomyositis (JDM) revealed increased 
echointensity with low to normal muscle thickness (32). These findings indicate that QMUS 
could be useful for the diagnosis of IIM, however further validation is needed. 
To date, information about large followed cohorts of IIM, including information on auto-
antibodies, complications and treatment are scares. The Nijmegen Myositis cohort, in 
which all studies described in this thesis were performed, provides insights in the above 
mentioned aspects.
16
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Nijmegen Myositis Cohort
In the Nijmegen Myositis cohort data from patients with IIM were retrospectively collected 
from March 10th 1978 until June 18th 2013. This cohort includes all patients with IIM from 
the Computer Registry of All Myopathies and Polyneuropathies (CRAMP) treated at the 
Radboud University Medical Center (35). The CRAMP is a Dutch multicentre neuromuscular 
registry and was developed in 2004. In addition, health care administrative data were used 
to include patients from before 2004 or patients solely treated by a rheumatologist (not 
registered in CRAMP). 
The data available of the Nijmegen Myositis cohort consist of demographic and 
clinical features at diagnosis combined with follow-up information on treatment, 
biochemical markers, pulmonary function test results and if indicated HRCT scans 
and echocardiography. Patients of the Nijmegen Myositis Cohort participated in the 
performed studies in this thesis. 
The Nijmegen Myositis Cohort consists of 125 patients with IIM namely 53 patients with 
PM, 54 patients with DM and 18 patients with overlap myositis (see Table 2). The mean age 
at diagnosis was 55.7 years (SD 17.2) for the total group of IIM, 58.3 years (SD 16.2) (PM), 
52 years (SD 17.2) (DM) and 58.3 years (SD 18.6 years) (overlap myositis). The majority of 
the patients were female (n = 76, 60%), especially in DM and overlap myositis group, but 
not in the PM group were the majority was male (n = 30, 57%).
Serology
The Myositis specific auto-antibodies (MSA) anti-Jo1, was present in 24% of the total 
IIM group, 36% (PM group), 20% (DM group) and 6% in the overlap myositis group. 
Unfortunately, other MSA were not available in our cohort due the fact that myositis blots 
became available in 2013 in daily clinical practice in our institute. The overlap myositis 
group revealed relevant presence of anti-SSA of 33%, anti-RNP 11%, anti-centromere 22% 
and 5 patients with anti-dsDNA antibodies. 
Diagnosis
For diagnosis of IIM the Bohan and Peter criteria were used. In the vast majority of the 
patients in the cohort an electromyography (EMG) (73%) and/or muscle biopsy (75%) 
was performed. Results of both investigations were consistent with myopathic findings in 
most patients. 
Clinical characteristics
Arthritis was seen in all groups; 26% in the total IIM group, 23% in PM, 19% in DM and 56% 
in overlap myositis group. The same holds true for Raynaud’s phenomenon: 42 patients 
(34%) in total IIM group, 16 patients (30%) in PM, 12 patients (22%) in DM and 14 patients 
17
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(78%) overlap myositis group. Interstitial lung disease (ILD) was diagnosed with the HRCT-
scan. ILD was present in 43% of the total IIM group, 52% in PM group, 41% in DM group 
and 27% in the overlap myositis group (see Table 3). 
Echocardiography was not performed in all IIM patients, but only in patients with 
dyspnea. In 61 patients of our cohort echocardiography was performed and in six (10%) 
cases pulmonary hypertension was possible according to the echo, four of those patients 
were diagnosed with overlap myositis. Pericarditis was seen in one patient with overlap 
myositis. 
Malignancy
In total 12 patients (10%) suffered from a malignancy before or after diagnosis of IIM. In 
the PM group malignancies were present in six patients (all in n = 1: breast cancer, renal cell 
carcinoma, melanoma and testicular cancer, melanoma, esophagus carcinoma and lung 
carcinoma). Five of the DM patients had a malignancy (all in n = 1 basal cell carcinoma of 
the skin, mammary carcinoma and ovarian carcinoma, gastric carcinoma, leiomyosarcoma 
and ovarian carcinoma).
Mortality
Twenty patients (16%) in the total group of IIM died during median follow-up of 8.2 years 
(2.8-13.6 IQR), 19% of the PM patients and 7% of the DM patients (see Table 3). The 
mortality in overlap myositis patients was 33% and thus significant higher, this difference 
was again observed among the 5-year survival rates, 86% (total IIM group), 84% PM group, 
94% DM group and 65% in the overlap myositis group. The causes of death were myositis 
related (n = 12), malignancies (n = 4) and unknown cause (n = 4). Of these patients with 
myositis related causes of death, seven patients died due to ILD, three patients due to 
progressive heart disease and two patients due to aspiration pneumonia. 
Treatment
Methotrexate and azathioprine are considered as first-line of DMARD therapy for patients 
with IIM. As expected the majority of our patient used methotrexate or azathioprine, 36% 
and 40% (the total IIM group). More recent advances show that mycophenolate mofetil 
can be used as DMARD in patients with ILD. Only a small number of patients were treated 
with mycophenolate mofetil (< 5% in the total IIM group). Rituximab was used as second or 
third line of treatment, 11% total IIM group, 11% in PM group and 14% in DM group (see 
Table 3). 
The description of our Nijmegen Myositis cohort offer insight in clinical feautures, 
diagnostic findings, treatment and mortality. 
18
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Table 3 | Characteristics of Nijmegen Myositis cohort
Characteristics Total
n	=	125
PM
n	=	53
DM 
n	=	54
Overlap myositis
n = 18
Age	mean	in	years	(SD)	at	diagnosis 55.7 (17.2) 58.3 (16.2) 52.0 (17.2) 58.3 (18.6)
Sex	female	(%) 76/125	(61%) 23/53	(43%) 16/54	(70%) 15/18	(83%)
Disease	duration	in	years	median	(IQR) 8.2 (2.8-13.6) 6.9 (2.5-15.6) 8.9 (3.0-12.9) 5.0 (1.7-17.3)
Mortality 20/125	(16%) 10/53	(19%) 4/54	(7%) 6/18	(33%)
Survival	in	years	median	(IQR) 5.8 (2.3-12.6) 4.7 (1.9-12.9) 8.3 (2.7-12.9) 4.5 (1.7-7.6)
1-year	survival 93% 92% 94% 93%
2-year	survival 92% 92% 94% 86%
5-year	survival 86% 84% 94% 65%
Arthritis 32/125	(26%) 12/53	(23%) 10/54	(19%) 10/18	(56%)
Raynaud’s	phenomenon 42/125	(34%) 16/53	(30%) 12/54	(22%) 14/18	(78%)
Serology
ANA 83/113	(74%) 30/45	(67%) 35/49	(71%) 17/18	(94%)
Anti-SSA 29/109	(27%) 13/45	(29%) 10/46	(22%) 6/18	(33%)
Anti-SSB 6/109	(6%) 2/45	(4%) 2/46	(4%) 2/18	(11%)
Anti-RNP 11/109	(10%) 4/45	(9%) 1/46	(2%) 6/18	(33%)
Anti-SM 5/109	(5%) 2/45	(4%) 0/46 3/18	(17%)
Anti-Jo1 26/109	(24%) 16/45	(36%) 9/46	(20%) 1/18	(6%)
Anti-Scl70 1/109	(1%) 1/45	(2%) 0/46 0/18
Anti-Centromere 6/109	(6%) 1/45	(2%) 1/46	(2%) 4/18	(22%)
Anti-Histon 2/109	(2%) 1/45	(2%) 0/46 1/18	(6%)
IgM	rheumatoid	factor 4/11	(36%) 4/5	(80%) 0/5 0/1
Anti-CCP 3/8	(38%) 2/3	(67%) 0/2 1/3	(33%)
Anti-dsDNA 5/5	(100%) NA NA 5/5	(100%)
EMG and Muscle biopsy
EMG	with	myopathic	findings 83/93	(89%) 35/41	(85%) 35/39	(90%) 12/12	(100%)
EMG	with	spontaneous	activity 50/93	(54%) 18/41	(44%) 23/39	(59%) 8/12	(67%)
Myopathic	muscle	biopsy 68/95	(72%) 32/45	(71%) 25/37	(68%) 10/12	(83%)
Internal organ involvement
HRCT	with	lung	fibrosis 27/63	(43%) 13/25	(52%) 11/27	(41%) 3/11	(27%)
Cardiac	ultrasound	with	signs	of	PH 6/61	(10%) 2/28	(7%) 0/20 4/12	(33%)
Cardiac	ultrasound	with	pericarditis 1/61	(2%) 0/28 0/20 1/12	(8%)
Malignancy 12/125	(10%) 6/53	(11%) 5/54	(9%) 1/18	(6%)
Treatment with DMARDs
Methotrexate 45/125	(36%) 16/53	(30%) 25/54	(46%) 4/18	(22%)
Azathioprine 50/125	(40%) 24/53	(45%) 21/54	(38%) 5/18	(27%)
Mycophenolate	mofetil 6/125	(5%) 2/53	(3%) 2/54	(3%) 2/18	(11%)
Cyclophosphamide 14/125	(11%) 7/53	(13%) 4/54	(7%) 3/18	(16%)
Ciclosporine 6/125	(5%) 2/53	(3%) 4/54	(7%) 0
Tacrolimus 3/125	(2%) 1/53	(1%) 2/54	(3%) 0
Immunoglobulin 5/125	(4%) 0 2/54	(3%) 0
Rituximab 14/125	(11%) 6/53	(11%) 8/54	(14%) 0
PM = Polymyositis; DM = Dermatomyositis; SD = standard deviaton; IQR = Interquartile range; HRCT= High resolution 
computed tomography; PH = Pulmonary hypertension; DMARDs = Disease-modifying anti-rheumatic drugs
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Aim and outline of the thesis
The main objectives of these thesis were to study the clinical aspects and outcome of 
patients with idiopathic inflammatory myopathies (Part I) and the diagnostic properties of 
Quantitative Muscle UltraSound (QMUS) in these patients (Part II). 
Chapter 1 is the introduction of the thesis.
Part I
–  Chapter 2 describes a study in which different types of pulmonary hypertension (PH) 
were identified in patients with IIM. 
–  Chapter 3 presents the result of a descriptive study of clinical and myopathological 
features of patients with systemic sclerosis-polymyositis overlap (SSc-PM overlap).
–  Chaptor 4 reports on the mortality of patients with SSc-PM overlap compared to 
patients with systemic sclerosis.
Part II
–  Chapter	5 contains results of our QMUS diagnostic accuracy study of patients suspected 
for IIM.
–  In Chapter	6, results are given of a muscle ultrasound study that assess the presence of 
a fasciitis among patients with IIM.
–  Chapter 7 evaluates the role of QMUS at diagnosis and remission in patients with 
juvenile dermatomyositis (JDM).
Chapter 8 is a summary and general discussion of the preceding chapters.
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Abstract
Objective To characterize the different types of pulmonary hypertension (PH) among 
patients with idiopathic inflammatory myopathy (IIM). 
Methods A retrospective case series with assessment of PH by right heart catheterization 
(RHC), extent of interstitial lung disease (ILD) and outcome of vasoactive therapy. 
Results The group of IIM patients with PH (n = 9) showed a median age at PH diagnosis of 
62 years (IQR 48-71); 8 females; 7 polymyositis and 2 dermatomyositis; median disease 
duration of 5.7 years and 5 patients with a positive anti-Jo1 antibody. We found 1 patient 
to be classified in PH WHO group 2 (left heart disease), 5 patients in WHO group 3 (lung 
disease) and 3 patients in WHO group 1 pulmonary arterial hypertension (PAH). During 
median observed follow-up of 24 months mortality for the total group was 44%. 
Conclusions Surprisingly we found a relevant group (33%) of IIM patients suffered from 
non ILD-PH, which reflects the presence of pulmonary arterial hypertension (PAH) 
phenotype. This result should lead to more awareness among treating physicians that 
complaints of dyspnea among patient with IIM could be related to PAH and not only ILD. 
The role of vasoactive therapy remains to be defined in patient with IIM suffering from 
PAH or PH-ILD.
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Introduction
Pulmonary hypertension (PH) is a life-threatening condition presenting with symptoms 
like breathlessness, fatigue and syncope (1). Pulmonary hypertension can occur as a 
complication of systemic autoimmune diseases (2-4). The association with polymyositis 
(PM) and dermatomyositis (DM), together classified as idiopathic inflammatory myopathy 
(IIM), is not well known (5). So far, only a few cases reported on PH in IIM patients (6-11). 
However, 2 recent cohort studies among antisynthetase patients, revealed a prevalence 
of PH ranging from 7.9% to 14.8% with a worsened prognosis (12, 13). These study results 
reflect the clinical relevance of PH as complication of IIM. 
PH patients can be classified according to the World Health Organization (WHO) 
classification in pulmonary arterial hypertension (PAH) (group 1), PH associated to left 
heart disease (group 2), PH associated to lung disease (group 3), chronic thromboembolic 
pulmonary hypertension (group 4) and PH with unclear mechanism (group 5) (14). The 
cause of pulmonary hypertension in the IIM patients with PH is however until now unclear. 
Although interstitial lung disease is frequently found among IIM patients, occurring in up 
to 65% of the patients (15), the question is whether this lung disease explains the presence 
of pulmonary hypertension in all IIM patient. In addition, data on long term follow up is 
scarce.
For this, we describe the clinical characteristics and follow up of nine IIM patients with 
pulmonary hypertension and investigated the cause and consequence of pulmonary 
hypertension in these patients.
Methods
This is a retrospective case series which consisted of IIM patients (n = 9) with PH of 2 
Dutch university hospitals, (Radboud University Medical Center, Nijmegen) (n = 4) and 
(VU University Medical Center, Amsterdam) (n = 5) which are both expert centers for 
PH. According to Dutch law and regulations, the study was exempted from approval of 
a medical ethical committee and no informed consent was required, since this was an 
observational, non-interventional study.
Participants
All IIM patients fulfilled at least the criteria for probable IIM according to the ENMC 
classification criteria (16). PH was defined as an increase in mean pulmonary arterial 
pressure (mPAP) ≥ 25 mmHg assessed with RHC (14). All known patients with IIM and PH 
were included at both Medical Centers (VU University Medical Center a registry of PH 
patients; Radboud University Medical Center Myositis Nijmegen cohort).
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Interstitial lung disease
Presence of extensive ILD was defined as signs of pulmonary fibrosis on HRCT scan 
with > 10% lung involvement. Limited ILD was defined as extent of lung parenchymal 
involvement ≤ 10% on HRCT which is a conservative cutt-off in comparison with staging 
system of Goh et al. (≤ 20%) (17). In remaining cases with an indeterminate extent on HRCT 
an abnormal pulmonary function tests (Total lung capacity: TLC: < 70% predicted was 
used to classify extensive ILD. A blinded pulmonologist (AV) retrospectively reviewed all 
available HRCT scans using the Wells method to score the presence and extent of ILD (18). 
Hemodynamics RHC
Based on PCWP PH can be divided into pre-capillary PH (PCWP ≤ 15 mmHg) and post-
capillary PH (PCWP > 15 mmHg), which can be related to different clinical causes (14). 
Patients with pre-capillary PH and limited ILD were defined as non ILD-PH (reflecting PAH) 
whereas patients with pre-capillary PH and extensive ILD as ILD-PH. Other parameters 
which were assessed by RHC were pulmonary capillary wedge pressure (PCWP), cardiac 
output and pulmonary vascular resistance (PVR). Outcome of vasoactive therapy in PH-
IIM patients was evaluated by available information on mortality, hospital admissions, 
therapy adjustments and alterations of six-minute walking test (6MWT) or World Health 
Organization functional class (WHO-FC) (19). The WHO-FC system grades severity of 
limitations due to PH on scale of 1 (no limitations) to 4 (limitation of all exercise). 
Case report
Patients
Our cohort consists of nine patients of which seven patients were diagnosed with 
polymyositis and two with dermatomyositis. The median age at diagnosis of PH was 62 
years (IQR 48-68; 8 females). The median disease duration of IIM at diagnosis of PH was 
5.7 years (IQR 3-10.3). In five patients anti-Jo1 auto antibody was present (Table 1). 
Interstitial lung disease 
Signs of pulmonary fibrosis on HRCT scans were present in seven patients (88%), with 
scans performed in 8/9 patients. All seven patients had a pre-capillary PH. A Wells score 
of 3, presenting dominance of a reticular pattern (i.e. fibrosis) was present in 3 (38%) 
patients. The median lung involvement was 50% of the surface (range 0-90%) with 4 
patients ≥ 70% lung involvement on the scans. Three patients (37%) displayed none or 
limited lung involvement (surface ≤ 10%) (Table 1, patients 3, 5 and 9). 
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Table 1 | Clinical and hemodynamic characteristics of each patient at PH diagnosis
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PH characterization
Eight patients presented with pre-capillary PH. Chronic thromboembolic PH and 
multifactorial PH causes were excluded. One patient was diagnosed with post-capillary 
PH caused by severe aorta valve stenosis, PH WHO group 2 (Table 1).
Combining information on ILD with right heart catheterization data demonstrates that 
5/8 pre-capillary PH patients had a fair to severe lung fibrosis, while the other three 
patients had none to limited lung fibrosis. Those three patients were diagnosed with PAH 
associated to IIM, WHO group 1 (patient 3, 5 and 9). In these patients, pulmonary fibrosis 
was either absent or present in < 10% of the pulmonary surface (Table 1) The remaining 
five patients with fair to severe pulmonary fibrosis were classified as PH caused by ILD 
(PH-ILD), WHO group 3 (14).
Outcome
The total group of patients with IIM and PH revealed a mortality of four patients (44%) 
during a median observed follow-up of 16 months. Within 5 months of diagnosis of PH, 
two patients died (patients 4 and 5), one due to heart failure complicated by severe aorta 
valve stenosis. The other patients died as a result of respiratory failure complicated with 
pneumonia before vasoactive therapy could be started. 
Vasoactive therapy was initiated in seven patients with pre-capillary PH (Table 2). Therapy 
included the use of prostanoids, endothelin receptors antagonists and phospodiesterase 
type-5 inhibitors. Follow-up information was unavailable in one patient due to transfer 
to another hospital (patient 8). After start of therapy two patients revealed an increase 
of walking distance (18% and 9%) during 6 minute walking test after 2 and 12 months 
(patient 2 and 3). However, after initial improvement, one patient died 3 years later due 
to heart failure (patient 3). Stabilization of walking distance after 6 months was observed 
in one patient, after 2 years the patient died due to respiratory failure (patient 7). In one 
patient pulmonary heamodynamics returned to normal after 1 year therapy with bosentan 
(patient 6). The remaining two patients on PH therapy suffered from a slow progression on 
the WHO functional class (patient 1 and 9). 
Discussion
In this clinical case series we describe a group of nine PH-IIM patients followed at 2 
referral centers for PH. We found one patient to be classified in PH WHO group 2 (left 
heart disease), five patients in WHO group 3 (lung disease) and three patients in WHO 
group 1 (PAH). Our study confirms previous results, indicating that the majority of the PH 
in IIM can be classified as PH-ILD, WHO group 3 (6-12). However, PAH associated to IIM is a 
possibility, in this group occurring in 33% of the patients.
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The pathogenesis of PAH in IIM is unknown, however, involvement of pulmonary vessels by 
diffuse infiltrative and inflammatory processes is likely to contribute (5). An autopsy study 
among PM patients found suggestive changes for PAH by encroachment of the pulmonary 
blood vessel lumen with medial smooth muscle hyperplasia (20). More recently, a Swedish 
study demonstrated that sera of anti-Jo1 positive PM patients could activate endothelial 
cells in healthy lung tissue (21). Altogether, these findings reinforce the hypothesis of 
specific pulmonary vascular involvement in the etiology of PH among IIM patients and the 
role of anti-tRNA synthetase autoantibodies such as anti-Jo1 (5, 12, 20, 21). 
Interestingly, two out of the three patients with PAH revealed the lowest DLCO values 
in our study. This observation tends to suggest, conversely to PAH among patients with 
systemic sclerosis, that IIM patients with PAH are associated with low DLCO values in 
pulmonary function test (22, 23). 
Although small retrospective studies suggested that specific PAH therapy may be used 
in the presence of severe PH due to chronic lung disease, the benefit of this therapy still 
has to be demonstrated. In our cohort, initiation of PAH treatment was performed on 
discretion of the treating doctor, including six patients with ILD and one patient without 
ILD. Although our observations suggest some of our patients seem to benefit from such an 
approach, the uncontrolled nature of this observational study does not allow to draw any 
conclusions on the effectiveness of such an approach in PAH. 
 A recent French observational study showed a 3-year survival of 58% in PH antisynthetase 
patients (12). The overall mortality in our study was 44% which suggests that the presence 
of PH was associated with a worse survival. 
The strength of our study is the novelty of reporting cases of PAH among patients with IIM 
with complete RHC data.
A limitation of our study is that all patients were recruited from two tertiary referral PH 
expert centers, which could have lead to a selection bias. However, to study an uncommon 
complication (PH) in a rare disease (IIM) inevitably leads to multicenter recruitment at 
tertiary centers. Furthermore, limited serology data were available by which properly 
classification of the presence of antisynthetase syndrome and further determination of 
ANA positivity was not possible. 
Conclusions
In conclusion, in this study we found the presence of ILD-PH in the majority (55%) of the 
selected patients with IIM and PH. Surprisingly, a relevant group (33%) of IIM patients 
suffered from non ILD-PH, which reflects the presence of PAH phenotype on which 
connective tissue disease itself plays a role in the etiology. Vasoactive therapy could play 
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a role in the treatment for patient with IIM and PAH phenotype. Altogether, this result 
should lead to more awareness among treating physicians that complaints of dyspnea 
among patients with IIM could be related to PAH and not only ILD. Given the rarity of 
PH-IIM a joined international effort is required to obtain more insight in the different PH 
phenotypes and the optimal treatment strategy of this disease.
PULMONARY HYPERTENSION IN IIM
33
References 
1 Vonk MC, van Dijk AP, Heijdra YF, van der Heijden HF, Bredie SJ, van den Hoogen FH. 
Pulmonary hypertension: its diagnosis and management, a multidisciplinary approach. Neth 
J Med. 2005;63(6):193-8.
2 Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension 
in systemic sclerosis: the need for early detection and treatment. Intern Med J. 
2007;37(7):485-94.
3 Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective 
tissue disease. Rheum Dis Clin North Am. 2005;31(3):451-64, vi.
4 Heresi GA, Minai OA. Lupus-associated pulmonary hypertension: long-term response to 
vasoactive therapy. Respir Med. 2007;101(10):2099-107.
5 Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory 
myopathies and the lung. Eur Respir Rev. 2015;24(136):216-38.
6 Yaqub S, Moder KG, Lacy MQ. Severe, reversible pulmonary hypertension in a patient with 
monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc. 2004;79(5):687-9.
7 Minai OA. Pulmonary hypertension in polymyositis-dermatomyositis: clinical and 
hemodynamic characteristics and response to vasoactive therapy. Lupus. 2009;18(11):1006-
10.
8 Taniguchi Y, Horino T, Kato T, Terada Y. Acute pulmonary arterial hypertension associated 
with anti-synthetase syndrome. Scand J Rheumatol. 2010;39(2):179-80.
9 Chatterjee S, Farver C. Severe pulmonary hypertension in Anti-Jo-1 syndrome. Arthritis Care 
Res(Hoboken). 2010;62(3):425-9.
10 Handa T, Nagai S, Kawabata D, Nagao T, Takemura M, Kitaichi M, et al. Long-term clinical 
course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and 
severe pulmonary hypertension. Intern Med. 2005;44(4):319-25.
11 Cavagna L, Prisco E, Montecucco C, Caporali R. Pulmonary arterial hypertension in 
antisynthetase syndrome: comment on the article by Chatterjee and Farver. Arthritis Care 
Res (Hoboken). 2011;63(4):633-4
12 Hervier B, Meyer A, Dieval C, Uzunhan Y, Devilliers H, Launay D, et al. Pulmonary 
hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J. 
2013;42(5):1271-82.
13 Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-
Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. 
Ann Rheum Dis. 2014;73(1):227-32.
14 Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines 
for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the 
Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology 
(ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European 
Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung 
Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-75.
15 Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: 
progress and pitfalls. Curr Opin Rheumatol. 2010;22(6):633-8.
16 Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC 
international workshop: trial design in adult idiopathic inflammatory myopathies, with 
the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. 
Neuromuscul Disord. 2004;14(5):337-45.
17 Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial 
lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 
2008;177(11):1248-54.
CHAPTER 2
34
18 Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM. The predictive value 
of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir 
Dis. 1993;148(4 Pt 1):1076-82.
19 McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early 
detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical 
practice guidelines. Chest. 2004;126(1 Suppl):14S-34S.
20 Denbow CE, Lie JT, Tancredi RG, Bunch TW. Cardiac involvement in polymyositis: a 
clinicopathologic study of 20 autopsied patients. Arthritis Rheum. 1979;22(10):1088-92.
21 Barbasso Helmers S, Englund P, Engstrom M, Ahlin E, Fathi M, Janciauskiene S, et al. Sera 
from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce 
expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis 
Rheum. 2009;60(8):2524-30.
22 Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of 
pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective 
multicenter study. Arthritis Rheum. 2005;52(12):3792-800.
23 Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography 
and pulmonary function as screening tests for pulmonary arterial hypertension in systemic 
sclerosis. Rheumatology (Oxford). 2004;43(4):461-6.

36
37
CLINICAL AND MYOPATHOLOGICAL FEATURES IN SSC-PM OVERLAP
CHAPTER 3
Scleroderma-polymyositis overlap 
syndrome versus idiopathic 
polymyositis and systemic sclerosis: a 
descriptive study on clinical features 
and myopathology
 
K.J. Bhansing, M. Lammens , H.K.A. Knaapen, P.C.L.M. van Riel,  
B.G.M. van Engelen, M.C. Vonk
Arthritis Res Ther. 2014;13;16:R111
38
CHAPTER 3
Abstract
Objective To characterize the clinical and myopathological features of patients with SSc-
PM overlap compared to a population of patients with SSc and PM. 
Methods A three-way comparison of patients with SSc-PM overlap (n = 25) to patients with 
SSc (n = 397) and PM (n = 40) on clinical and myopathological features and causes of death. 
One neuropathologist blinded for the diagnosis evaluated all recent available muscle 
biopsies. Biopsies were scored for presence of inflammation, necrotic muscle fibers, 
rimmed vacuoles, fibrosis and immunohistochemical staining. Clinical or myopathological 
characteristics were compared using the Chi-square test or one-way ANOVA. 
Results The prevalence of SSc-PM overlap in the Nijmegen Systemic Sclerosis cohort 
was 5.9%. The mortality was 32% (8/25) in SSc-PM, of which half was related to cardiac 
diseases. The prevalence of pulmonary fibrosis was significantly increased in SSc-PM 
(83%) (p = 0.04) compared to SSc (49%) and PM (53%). SSc or myositis specific antibodies 
were nearly absent in SSc-PM group. In almost all biopsies (96%) of SSc-PM patients 
necrotic muscle fibers were present, which was significantly increased compared to PM 
patients (p = 0.02).
Conclusions Patients with SSc-PM have increased prevalence of pulmonary fibrosis and 
cardiac disease as cause of death compared to patients with SSc and PM. In addition, 
we found that necrotizing muscle fibers with inflammation characterize SSc-PM overlap 
in muscle biopsies. Further research should focus on underlying mechanisms causing 
necrosis, inflammation and fibrosis and their relationship to pulmonary involvement and 
mortality in patients with SSc-PM overlap.
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Introduction
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by vascular 
lesions and fibrosis of multiple organs, predominantly in skin, lungs, heart, intestinal tract, 
joints and muscles (1, 2). The prevalence of myopathies in SSc patients varies from 5% to 
81%, depending on the use of different definitions of muscle involvement (3-11). Myositis 
in SSc patients resembles clinically and biological features of patients with polymyositis 
(PM), hence the term scleroderma/polymyositis overlap (SSc-PM). Previous studies 
demonstrated a worse survival and increased prevalence of myocardial involvement in SSc-
PM overlap compared to SSc (9, 12). Therefore, it seems clinical relevant to identify SSc-PM 
overlap for close monitoring and early treatment. To date, no studies have been conducted 
to characterize the full spectrum of SSc-PM overlap by means of a three-way comparison 
with SSc and idiopathic PM. Better understanding of similarities and differences in clinical 
and biological features as well as outcome may lead to improved treatment and prognosis 
for SSc-PM overlap patients.
The aim of this study is to characterize the clinical and myopathological features of patients 
with SSc-PM overlap patients compared to a population of patients with SSc and PM.
Methods
Design
The Nijmegen Systemic Sclerosis cohort is an ongoing, prospective inception cohort 
started in 1989 at the department of rheumatic diseases at the Radboud University 
Medical Center. The data collection contains information of symptoms, physical 
examination, laboratory work-up as well as annually performed pulmonary function test 
results, echocardiography, right heart catheterization and high density CT-scans (HRCT) 
scans at baseline and when indicated.
The Nijmegen Myositis cohort is also a prospectively followed cohort of patients with 
inflammatory myopathies. This cohort includes all patients with inflammatory myopathies 
from the Computer Registry of All Myopathies and Polyneuropathies (CRAMP) treated 
at the Radboud University Medical Center (13). The CRAMP is a Dutch multicentre 
neuromuscular registry and was developed in 2004. The data available of the Nijmegen 
Myositis cohort consist of demographic and clinical features at diagnosis combined with 
follow-up information on treatment, biochemical markers, pulmonary function test 
results and if indicated HRCT scans and echocardiography.
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Participants
All patients with SSc patients can be classified by the ACR preliminary classification 
criteria for SSc or Leroy criteria for early SSc. The patient with PM patients all fulfilled 
the Bohan and Peter diagnostic criteria, whereas the SSc-PM overlap participants fulfilled 
both criteria (14-17).
All SSc-PM patients of the Nijmegen Systemic Sclerosis cohort were included. SSc patients 
with serum CK more than 2 times upper limit, myalgia and proximal muscle weakness were 
analyzed for presence of polymyositis with electromyography (EMG) and muscle biopsy. 
All consecutive PM patients of the Nijmegen Myositis cohort were included. The study 
was exempted from approval of the local Medical Ethics Committee Arnhem-Nijmegen in 
the Netherlands, since this was an observational, non-interventional study. Therefore, no 
informed consent was required for this study. 
Myopathological analysis
The slides of all available muscle biopsies of SSc-PM (n = 24) and most recent consecutive 
patients with PM patients (n = 24) were used to pair with 1:1 ratio. One neuropathologist 
(ML), blinded for diagnosis, evaluated all muscle biopsies. Biopsies were scored for 
presence of inflammatory infiltrates, necrotic muscle fibers, fibrosis, rimmed vacuoles and 
if performed for enzyme histochemistry for Cytochrome C-oxidase (COX) and Succinate 
dehydrogenase (SDH) and immunohistochemistry for MHC class I, membrane attack 
complex (MAC), CD 4, CD 8, CD 20, and CD 68. Inflammatory infiltrates were defined as 
presence of mononuclear cell infiltrates surrounding or invading muscle fibers. Necrosis in 
muscle biopsy was defined as presence of acute necrotic muscle fibers, that were identified 
on haematoxylin–phloxine staining (paling of the cytoplasm and absence of basophilia), 
myophagia or the presence of regenerating basophilic fibers. Fibrosis was defined as 
increase of collagen and fibroblasts in the endomysium. MHC class I upregulation was 
regarded positive if at least the sarcolemma expressed MHC class I antigen (18). MAC 
upregulation was regarded present if MAC was expressed in the endothelium of capillaries 
or in the sarcoplasm of muscle fibers (19, 20).
Statistical analysis
Statistical analysis was performed with SPSS version 20 for Windows (SPSS Inc., 
Chicago, Illinois, USA). Study population and muscle biopsy characteristics were 
compared with the Chi-square test or Fisher’s exact test for nominal data and Mann-
Whitney U test for numerical data or one-way ANOVA. Statistical significance was 
defined as p-value ≤ 0.05.
41
CLINICAL AND MYOPATHOLOGICAL FEATURES IN SSC-PM OVERLAP
Results
The mean age at diagnosis was 53 years (SD 12.3) (SSc-PM overlap), 50 years (SD 13.2) 
(SSc) and 51 years (SD 16.5) (PM). The median disease duration was 5.0 years (IQR 2.8-
12.4), 7 years (IQR 3-14) and 3.5 years (IQR 2-11) respectively. The SSc-PM group was 
characterized by an almost 1:1 female/male ratio whereas SSc group by 2:1 female to male 
ratio and the PM group by an almost opposite ratio of 1:2. (Table 1). The prevalence of SSc-
PM overlap in the Nijmegen Systemic Sclerosis cohort was 5.9%
Serology
SSc specific auto antibodies, namely anticentromere and antitopoisomerase 1, were 
nearly absent in the SSc-PM group and present in 19% and 22% of the SSc patients. None 
of the PM patient tested positive for anticentromere and antitopoisomerase 1, except one 
PM patient. Myositis associated antibody, anti-SSA and myositis specific antibody, anti-
Jo1, were significantly less present in SSc-PM group compared to the PM groups. (Table 1).
Table 1 | Study population characteristics
Characteristics No. SSc-overlap
(n	=	25)
No. SSc 
(n	=	397)
No. PM
(n	=	40)
P-value
Age	in	years	mean	(SD) 25 53 (12.3) 397 50 (13.2) 40 51 (16.5) 0.013
Sex	(Male/female) 25 12/13 397 131/266 40 25/15 0.003
Limited	cutaneous	SSc	 19	(76%) 276	(73%) NA NS
Diffuse	cutaneous	SSc 6	(24%) 109	(27%)
Disease	duration	years	median	
(IQR)	
25 5 (3-12) 397 7 (3-14) 40 3.5 (2-11) 0.001
Mortality 25 8	(32%) 397 65	(16%) 40 7	(18%) NS
Survival	in	years	median	(IQR) 8 2.5 (1.3-9.6) 65 7 (3-13.5) 7 0.3 (0-12) NS
Serology
ANA 25 25	(100%) 397 356	(90%) 34 21	(62%) 0.006
Anti-topoisomerase	 21 0 397 87	(22%) 31 1	(3%) 0.048
Anti-centromere 19 2	(10%) 397 76	(19%) 31 0 NS
Anti-SSA 25 2	(8%) 397 15	(4%) 31 11	(36%) <	0.001
Anti-SSB 25 0 NA 31 1	(3%) NS
Anti-RNP 25 2	(8%) 397 27	(7%) 31 2	(6%) NS
Anti-SM 25 0 NA 31 2	(6%) NS
Anti-Jo1 25 2	(8%) NA 31 13	(42%) 0.013
No. = number of patients; SSc = systemic sclerosis; PM = Polymyositis; SD = Standard Deviation; NA = not 
applicable; NS = not significant; IQR = Interquartile range
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Scleroderma and myositis specific features
Raynaud’s phenomenon was present in all groups, 21 patients (84%) in SSc-PM overlap, 
379 patients (96%) in SSc, 13 patients (33%) in PM. The 13 (33%) patients with Raynaud’s 
phenomena in the PM group, suffered also from features such as mechanic hands, arthritis, 
ILD and were anti-Jo1 antibodies positive, reflecting the anti-synthetase syndrome. The 
median modified Rodnan skincore (mRSS) was 6 (IQR 5-11) in the SSc-PM group and 7 
(IQR 4-12) in the SSc group (Table 2).
Signs of myositis such as serum CK elevation (> 2 time ULN) and proximal muscle weakness 
were present in 48 SSc patients (12%) and in 21 SSc patients (5%) respectively (Table 1). 
Arthritis was present in all three groups with a prevalence ranging from 12% to 20%.
Interstitial lung disease
Interstitial lung disease (ILD) was diagnosed in patients whether moderate to severe 
pulmonary fibrosis was present on the HRCT-scan. The presence of ILD was statistically 
significant higher in the SSc-PM overlap group compared to the other two groups. 
Furthermore, there was a significant higher prevalence of decreased lung carbon monoxide 
diffusion capacity (defined as TLCO ≤ 70%) in the SSc-PM overlap group (Table 2).
Cardiac complications
Diastolic dysfunction on echocardiography was present in all three groups. Right heart 
catheterization (RHC) was only performed when pulmonary hypertension (PH) was 
suspected at echocardiography or in cases with unexplained dyspnea or an isolated 
decrease of carbon monoxide (CO) diffusion capacity at pulmonary function testing. 
PH was diagnosed in none of the SSc-PM overlap patients, 57 SSc patients and in one 
PM patient. When no RHC was performed, we assumed that PH was absent. With this 
assumption we found a statistically significant increase of PH in SSc patients compared to 
the other groups.
Malignancy
In the SSc-PM overlap group one patient developed a squamous cell carcinoma in the 
neck and one patient developed a basal cell carcinoma of the skin on the forehead. In five 
patients in the PM group a malignancy was diagnosed during follow-up, consisting of renal 
cell carcinoma (n = 1), melanoma (n = 1), breast cancer (n = 1), esophagus carcinoma (n = 1) 
and lung carcinoma (n = 1). Data concerning number and type of malignancy cases were 
not available in the SSc group.
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Table 2 | Disease specific characteristics
 
Characteristics No. SSc-overlap 
(n	=	25)
No. SSc 
(n	=	397)
No. PM
(n	=40)
P-value
Scleroderma features
Raynaud’s	phenomena 25 21	(84%) 397 379	(96%) 40 13	(33%) <	0.001
Digital Ulcers 25 6	(24%) 397 164	(41%) 40 3	(8%) <	0.001
Pitting	Scars - 397 160	(40%) NA NA
mRodnan skin score (median) 15 6 (5-11) 372 7 (4-12) NA NS
Renal Crisis 25 1	(4%) 397 17	(4%) NA NS
Myositis features
Serum	CK	elevation‡ 25 24	(96%) 397 48	(12%) 40 34	(85%) <	0.001
Proximal	muscle	weakness 25 25	(100%) 397 21(5%) 40 37	(93%) <	0.001
Myopathic	EMG	findings 25 22	(88%) NA 29 24	(83%) NS
Mechanic hands NA NA 40 7	(18%) NS
Internal Complications
Arthritis 25 5	(20%) 397 46	(12%) 40 7	(18%) NS
Interstitial	lung	disease
HRCT	fibrosis 18 15	(83%) 346 170	(49%) 19 10	(53%) 0.044
TLC	≤	70%	of	predicted 21 4	(19%) 364 68	(19%) 23 9	(39%) NS
TLCO	≤	70%	of	predicted 17 17	(100%) 347 260	(75%) 20 13	(65%) 0.001
Diastolic	dysfunction	by	cardi-
ac	ultrasound
19 7	(37%) 352 146	(42%) 19 4	(21%) NS
PH	suspicion	by	cardiac	
ultrasound
20 3	(15%) 352 89	(25%) 19 2	(11%) 0.042
PH	by	cardiac	catherization 5 0 182 57	(31%) 2 1	(50%) 0.002
Myocarditis 25 1	(4%) NA 40 0 NS
Malignancy 25 2	(8%) NA 40 5	(13%) NS
No. = number of patients; SSc = Systemic sclerosis; PM = Polymyositis; NA = not applicable; NS = not significant; 
TLC = total lung capacity; HRCT = high-resolution CT scan; TLCO = Transfer Factor of the Lung for Carbon 
Monoxide; PH = Pulmonary hypertension; † defined as statistical significant ‡ Defined > 2 times upper limit of 
normal (ULN)
Mortality
Eight patients (32%) in the SSc-PM overlap group died, which was not statistically 
significant increased compared with the other groups (Table 1). The causes of death were 
progressive heart disease (n = 2) , myocardial infarction (n = 2) , respiratory failure due 
to interstitial lung disease (ILD) (n = 1) , sepsis (n = 2) and unknown cause (n = 1). Causes 
of mortality in the SSc group were progressive heart failure (n = 7) 10.8%, myocardial 
infarction (n = 2) 3.1%, respiratory failure due to ILD (n = 11) 16.9% or pulmonary 
hypertension (n = 13) 20%, malignancies (n = 6) 9.2%, infections (n = 6) 9.2% and other or 
unknown causes (n = 20) 30.8%. In the PM group seven patients died. Their causes of death 
were progressive heart disease (n = 2), aspiration pneumonia (n = 2), malignancy (n = 2) and 
unknown cause (n = 1). 
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Myopathology
All muscle biopsies were assessed by the same neuropathologist who was blinded for the 
clinical diagnosis, and his findings are shown in Table 3 and Figure 1. We found a statistically 
significant difference in the presence of necrotic muscle fibers, which was present in 96% 
of the SSc-PM biopsies compared to 67% of the PM biopsies. This significant difference 
was mostly caused by difference in presence of acute necrotic muscle fibers (50% vs. 
29.2%).
The presence of inflammatory markers such as lymphocytic infiltrates (63% vs. 54%) 
and positive MHC I staining (92% vs. 78%) were not significant different among the SSc-
PM overlap patients compared to the PM patients. Also fibrosis displayed quite similar 
rates of presences between both groups. None of the muscle biopsies revealed rimmed 
vacuoles, ruling out inclusion body myositis (21). On characterization of different types 
of lymphocytes only limited data was available. Deposition of MAC was only found in 
necrotic muscle fibers and not in the capillaries. COX and SDH staining was more often 
applied on the specimens and in a small number of cases (n = 3) in SSc-PM and (n = 6) in PM 
revealed presence of COX-negative muscle fibers. 
Table 3 | Myopathological markers of muscle biopsies slides
Characteristics No. SSc-overlap
(n	=	24)
No. PM
(n =	24)
Significance	
(p-value)
Necrotic	muscle	fibers 24 23	(96%) 24 16	(67%) 0.023†
Lymphocytic	infiltrates 24 15	(63%) 24 13	(54%) NS
Positive MHC class I staining 12 11	(92%) 18 12	(67%) NS
Inflammation* 24 19	(79%) 24 18	(75%) NS
MAC° staining 10 5	(50%) 13 5	(39%) NS
Fibrosis 19 5	(26%) 24 2	(8%) NS
Presence	of	COX-negative	fibers 10 3	(30%) 10 6	(60%) NS
No. = number of patients; NA = not applicable; NS = not significant; SSc = Systemic sclerosis; PM = Polymyositis
*Inflammation is defined as positive MHC class I staining or/and presence of lymphocytic infiltrates
† defined as statistical significant
° MAC: Membrane attack complex
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              Left side (A, C, E): SSc-overlap patient                                  Right side (B, D, F): PM patient
Figure 1 | Histopathological muscle biopsy images of SSc-PM overlap patient vs. PM patient
A. Hematoxylin and eosin (HE) stain, upper marker = necrosis, lower marker = lymphocytic 
infiltrate; B. HE stain, marker = lymphocytic infiltrate; C. MAC stain, markers = MAC upregulation 
D. MAC stain, no upregulation; E. MHC class I stain, sarcolemmal MHC class I upregulation; 
F. MHC class I stain, sarcolemmal and diffuse cytoplasmic MHC class I upregulation
 
Discussion
In this study we describe and compare both the clinical characteristics and 
myopathological findings of patients with SSc-PM overlap, SSc and PM. In our study 
we found an increased prevalence of pulmonary fibrosis among patient with SSc-PM 
overlap which is in accordance with a Japanese study which also showed an increased 
presence of ILD among patients with SSc-PM overlap compared to patients with SSc (7). 
However, an increased presence of ILD was not confirmed in a French study (22). ILD can 
cause early death and can diminish the quality of life due to symptoms of dyspnea and 
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fatigue. However, no significant difference was found in ILD associated death between the 
patients with SSc-PM overlap, SSc and PM. However, our study only contains a small study 
population which limits a proper survival analysis with ILD. The increased prevalence of 
ILD in overlap patients should warrant regular screening for this complication and timely 
initiation of specific immunosuppressive therapy. Further studies should focus on the 
extent of pulmonary fibrosis and related morbidity among SSc-PM patients.
Several studies have described increased myocardial involvement such as diastolic or 
systolic dysfunction and myocarditis in patients with SSc associated myopathies (7, 9, 22, 23). 
We found no statistically significant difference in myocardial involvement between the 
three patient cohorts in our study, but we used echocardiography as a screening tool and 
cardiac MRI was not performed routinely. Echocardiography lacks specificity to accurately 
diagnose myocarditis, so the prevalence of this complication could prove to be higher if a 
cardiovascular MRI was performed as well (24). In our cohort, we found progressive heart 
disease to be the cause of death in 25% of our overlap patients compared to only 10.8% of 
SSc patients. 
The prevalence of SSc-PM overlap in our Nijmegen Systemic Sclerosis cohort was low 
(5.9%) compared to older investigations (3-7, 9). In more recent studies, prevalences of 7.6% 
and 7.2% (22, 25) were observed, which is comparable to our finding. This discrepancy in 
prevalences compared to more dated studies can be explained by the different criteria 
used to define SSc myopathy and the different study designs. In our study we used strict 
criteria to select only inflammatory myopathies among SSc patient and not associated 
myopathies. Furthermore, this investigation only includes clinically relevant causes, 
whereas Medsger et al reports 90% prevalence of proximal muscle weakness of which only 
20% complained of muscle related symptoms (3).
Different antibodies are associated with SSc-PM overlap such as anti-PM/Scl and anti-
Ku (26, 27). More recent studies show novel antibodies related to SSc-PM, anti-U3 RNP 
and anti-RuvBL1/2, respectively (28, 29). These antibodies relate to different clinical 
manifestation of SSc-PM overlap patients, for example Caucasian patients with limited 
cutaneous involvement and pulmonary fibrosis (antiPM/Scl) or African male patients with 
diffuse cutaneous involvement and pulmonary arterial hypertension (anti-U3 RNP) (26, 28). 
Unfortunately, no data concerning SSc-PM overlap associated antibodies were available, 
which can be regarded as a limitation to our study.
We studied muscle biopsies of both overlap and PM patients, blinded for the diagnosis. 
For the first time, our study revealed that the myopathology in patients with SSc-PM 
overlap syndrome shows specific features compared to PM patients. Necrotizing muscle 
fibers were observed in almost all SSc-PM overlap samples. In the majority of the SSc-
PM muscle biopsies features of inflammation were also found, enabling us to exclude 
the histopathological diagnosis of a necrotizing myopathy according to the European 
Neuromuscular Centre workshop 2003 (30). A French study showed a slightly lower 
47
CLINICAL AND MYOPATHOLOGICAL FEATURES IN SSC-PM OVERLAP
prevalence of 25/35 (63%) of necrotic muscle fibers among their cohort of SSc-PM overlap 
patients (8). However, when including the presence of regenerating (i.e. basophilic) muscle 
fibers, a feature present after necrosis, the prevalence of necrosis is in accordance with our 
findings. 
MAC staining is often used to analyze muscle biopsies for signs of dermatomyositis (DM) 
if present as linear deposits at endothelial cells of endomysial capillaries (19, 20). This was 
not present in our study. We observed MAC staining in the sarcoplasm which is indicative 
of necrotic fibers. No presence of rimmed vacuoles is found in this study. This verifies that 
our PM muscle biopsies are homogenous for that diagnosis and are unlikely to include 
patients with IBM or DM.
The presence of COX-negative muscle fibers might be indicative for mitochondrial 
abnormalities. There is growing evidence that mitochondrial abnormalities can be found 
in dermatomyositis, inclusion body myositis and very seldom in polymyositis (21, 31). The 
results of our study revealed a small number of cases with COX-negative fibers. Only two 
PM patients had more than a single affected muscle fiber, but both patients were aged 
over 65 years and in these cases the COX-negative fibers may be considered as an effect 
of ageing. Therefore, we conclude that there is no evidence for mitochondrial pathology in 
patients with SSc-PM overlap.
This study has several limitations. All the subject were recruited from a single, tertiary 
referral centre, which may have lead to a bias towards more severe cases. However, 
this is true for all three patient cohorts and therefore it would less likely bias observed 
differences among the patient cohorts. The small sample size of SSc-PM overlap cohort 
makes us cautious for over-interpretation of results. Nonetheless, using strict criteria, 
we were able to identify a well-defined homogenous overlap cohort. Furthermore, the 
blinded for diagnosis expert assessment of overlap muscle biopsies in comparison with 
PM biopsies is unique and greatly increased the strength of our findings. 
Conclusions
In conclusion, in our study we found a prevalence of 5.9% of SSc-PM overlap in the 
Nijmegen Systemic Sclerosis cohort. Secondly we observed an increased proportion of 
pulmonary fibrosis among patients with SSc-PM overlap. Thirdly, we revealed that cardiac 
complications are a major cause of death in patients with SSc-PM overlap. Consequently, 
we urge for more active and regular cardiopulmonary screening among these SSc-PM 
patients. Fourthly, we found that necrotizing muscle fibers with inflammation characterize 
SSc-PM overlap in muscle biopsies. Further research should focus on underlying 
mechanisms causing necrosis, inflammation and fibrosis and their relationship to 
pulmonary involvement and mortality in SSc-PM overlaps patients in order to optimize 
treatment, increase survival and improve quality of life. 
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Abstract
Objective Studies on mortality associated with patients with systemic sclerosis (SSc) 
and myopathy have been limited by heterogeneous definitions of muscle involvement. 
The objective of this study is to determine whether homogeneous defined scleroderma/
polymyositis overlap (SSc-PM overlap) is associated with a worse survival compared to SSc 
without polymyositis.
Methods Data from the Nijmegen Systemic Sclerosis cohort were used. Incidence rates 
were calculated from the observed number of deaths and follow-up time. Survival analysis 
using Cox proportional hazard modeling was performed to compare survival among 
patients with SSc and patients with SSc-PM overlap, including controlling for confounders. 
All SSc-PM patients fulfilled ENMC international workshop criteria for polymyositis. 
Results There were 24 (5.7%) SSc-PM patients and 396 (94.2%) SSc patients. The 5- and 
10-year cumulative survival from diagnosis were 82% and 68% for the SSc-PM group and 
93% and 87% of the SSc group. Multivariate survival analysis revealed an adjusted hazard 
rate (HR) of 2.34 (95% CI 1.09-5.02) for SSc-PM compared to SSc, while age at diagnosis, 
modified Rodnan skin score, diffuse cutaneous subtype and male sex were included as 
confounders. The most common cause of death among patient with SSc-PM overlap was 
cardiopulmonary involvement (63%), which was similar to the patients with SSc (51%).
Conclusions Patients with SSc-PM overlap have a worse survival compared to patients 
with SSc. 
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Introduction
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by vascular 
lesions and fibrosis of multiple organs, predominantly in skin, lungs, heart, intestinal tract, 
joints and muscles (1, 2). The prevalence of myopathies reported in SSc patients varies from 
5% to 81%, also due to the use of different definitions of muscle involvement (3-12). Myositis 
in SSc patients resembles clinical and biological features of patients with polymyositis 
(PM), hence the term scleroderma/polymyositis overlap (SSc-PM) is used. 
SSc-PM is not benign; in several studies it appeared that the prevalence of myocardial 
involvement and pulmonary fibrosis is increased in patients with SSc-PM overlap 
compared to SSc patients (7, 9, 12). A possible explanation for a poor prognosis for SSc-PM 
overlap patients is that SSc-PM overlap could reflect a more active disease with increased 
presence of systemic complications (7, 9, 12). Increased mortality in patients with SSc and 
myopathy has been suggested in 2 recent studies (13, 14). However, both studies used 
heterogeneous definitions of SSc myopathy ranging from raised serum to CK to reported 
history of myositis. If indeed survival is worse in SSc-PM overlap patients compared to 
SSc patients, knowledge on the causes of death and organ involvement could support 
treatment decisions in order to improve survival.
Therefore, the objective of this study is to determine whether SSc patients with an overlap 
with polymyositis have a worse survival compared to SSc patients without polymyositis. 
Methods
Design
The Nijmegen Systemic Sclerosis cohort is an ongoing, prospective inception cohort 
which was started in 1989 at the department of Rheumatology at the Radboud University 
Medical Center. The data collection contains information on symptoms, physical 
examination, laboratory work-up as well as annually performed pulmonary function 
tests and echocardiography and high resolution computed tomography-scans (HRCT) at 
first visit and during follow-up when indicated. According to Dutch law and regulations, 
the study was exempted from approval of a medical ethical committee and no informed 
consent was required, since this was an observational, non-interventional study.
Participants
All patients with SSc or SSc-PM of the Nijmegen Systemic Sclerosis cohort were 
included. SSc patients were classified according to the preliminary American College of 
Rheumatology (ACR) classification criteria for SSc (15). The SSc-PM patients also fulfilled 
the Bohan and Peter criteria for probable or definite PM (16, 17). 
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Serum CK was routinely measured in all SSc patients. All SSc patients with a raise of serum 
CK of at least 2 times the upper limit, myalgia and proximal muscle weakness had been 
analyzed for presence of polymyositis with electromyography (EMG) and muscle biopsy. 
One experienced neuropathologist evaluated all muscle biopsies.
Survival and cause of death
Patients contributed person-years of follow-up for the period since first diagnosis of SSc as 
confirmed by a rheumatologist. Follow-up was terminated at the time of death, drop-out, 
or at the first of January 2012, whichever came first. The causes of death were retrieved 
from medical records or available autopsy reports. Death rate was calculated from the 
observed number of deaths divided by the number of patient-years, for SSc and SSc-PM 
groups separately.
Disease definitions
Presence of SSc and of SSc-PM was defined above. Diffuse cutaneous SSc (DcSSc) was 
defined as patients having skin thickening proximal to the elbows and knees during 
diagnosis. Limited cutaneous SSc (LcSSc) was defined as the presence of skin thickening 
distal to the elbows and knees, or in the face at least 2 years after the onset of the first non-
Raynaud phenomenon. First non-Raynaud phenomena consisted of proximal scleroderma; 
sclerodactyly; puffy hands (sausage-like finger edema lasting > 6 months, or lasting a 
shorter time but followed by sclerodactyly); or pulmonary fibrosis (18).
Skin involvement was evaluated during interval of 6 weeks after diagnosis using the 
modified Rodnan Skin Score (mRSS), which assesses the skin hardening/thickness by 
manual palpation of 17 body areas on a scale of 0 to 3 (19).
Renal crisis was defined by the occurrence of malignant arterial hypertension (diastolic 
blood pressure > 120 mm Hg) with grade III or IV hypertensive fundoscopic changes 
according to the Keith-Wagener classification) or rapidly progressive oliguric renal failure 
without other discernible causes during the course of SSc (20).
Interstitial lung disease (ILD) was defined as presence of significant pulmonary fibrosis on 
high-resolution CT-scan and forced vital capacity (FVC) < 70% of predicted normal and/or 
diffusing capacity of the lung for carbon monoxide (DLCO) < 70% of predicted.
Pulmonary hypertension was suspected if an experienced cardiologist found a tricuspid 
regurgitation velocity > 3 m/sec or 2.5-3 m/sec on echocardiography with unexplained 
dyspnea (21). Pulmonary hypertension was confirmed when the mean pulmonary arterial 
pressure was ≥ 25 mmHg at rest assessed with right heart catherization (22). Cardiac 
dysfunction was defined as a moderate to severe left ventricular systolic dysfunction on 
cardiac ultrasound or a wedge pressure > 15 mmHg measured at right heart catheterization 
(23). 
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Statistical analysis
We compared clinical characteristics of SSc and SSc-PM overlap patients at baseline 
using t test, Mann-Whitney U test and χ2 or Fisher’s exact test, as appropriate. Kaplan-
Meier cumulative survival plots were used to describe time until occurrence of death or 
censoring for SSc-PM and non SSc-PM patients. Survival analysis was carried out by a Cox 
proportional hazard model using the pooled dataset resulting from multiple imputation. 
Baseline variables (Table 1) were regarded as confounders if the regression coefficient of 
the main effect (SSc-PM overlap status) in the Cox proportional model changed by at least 
10% when adding the variable to the model using a forward selection approach. Serology 
and internal organ involvement variables were not included in the analysis, because they 
possibly serve as causal or explanatory variable regarding the risk difference between SSc 
and SSc-PM. The risk difference between SSc and SSc-PM overlap was given as adjusted 
hazard ratio (adjHRs) with 95% confidence interval (CI) when multivariate analysis was 
performed with correction for confounders.
The proportional hazard assumption was checked by graphical inspection of the linearity 
of the hazards over time and log-log plots. Sensitivity analysis was performed with a 
different value of the follow-up time: patient-years since last diagnosis was confirmed (i.e. 
when both SSc and/or PM diagnosis were confirmed and an overlap diagnosis exist). 
We performed all analyses with the SPSS package for Windows 20 (IBM Inc., New York, 
USA) and defined statistical significance as a p-value ≤ 0.05.
Missing data
Multiple imputation was used for missing values regarding confounders (age, gender, 
type of SSc and modified Rodnan skinscore) used in the Cox-survival model. Multiple 
imputation was carried out with a linear regression method with a random component, 
conditionally on data being missing at random (24). Confounding variables age, gender 
and type of SSc revealed no missing data. Only missing values of the modified Rodnan 
skinscore (mRSS) were imputed using SSc subset (limited/diffuse cutaneous) and mRSS at 
another time point as predictors. The modified skinscore was missing in 8% within interval 
of 6 weeks during diagnosis and calculated based on 5 imputed datasets. Missing value 
analysis showed no abnormal pattern.
Missing information for ILD was considered equivalent to no ILD, because patients with 
missing pulmonary function tests or HR-CT scans usually lacked documented pulmonary 
symptoms or physical findings. 
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Results
Patient characteristics
By January 2012, a total of 420 SSc patients followed for 4127 patient-years were included 
for the analysis. There were 396 (94.2%) SSc patients and 24 (5.7%) SSc-PM patients. The 
median (P25-P75) follow-up time in years for the SSc patients was 7.8 (3.9-14.1) and 6.3 
(4.2-12.9) for SSc-PM patients. 
Table 1 | Clinical characteristics of study population
Characteristics Total
(n	=	420)
SSc-PM patients
(n	=	24)
SSc patients
(n	=	396)
P-value
SSc-PM vs. SSc
Age	in	years	mean	(SD) 50 (13.1) 52 (12.1) 50 (13.2) 0.28
Sex,	female	(%) 273/420	(65%) 13/24	(54%) 260/396	(66%)	 0.25
Type	SSc	(Limited/diffuse	
cutaneous)
306	(73%)	/	114	(27%) 19	(79%)	/	5	(21%) 287	(73%)	/109	(27%) 0.47
Disease	duration	since	SSc	in	
years	median	(IQR)
7.8 (3.9-14.1) 6.3 (4.2-12.9) 7.8 (3.9-14.1) 0.85
Disease	duration	since	PM	in	
years	median	(IQR)
- 5.7 (3.8-12.9) - -
Mortality	(%) 73/420	(17%) 8/24	(33%) 65/396	(16%) 0.048
Scleroderma features
Raynaud’s	phenomena	(%) 400/420	(95%) 21/24	(88%) 379/396	(96%) 0.098
Digital Ulcers 169/420	(40%) 5/24	(21%) 161/395	(41%) 0.046
mRodnan skin score median 
(IQR)
7/386 (4-12) 6/15 (5-11) 7/371 (4-12) 0.96
Serology
ANA	(%) 318/420	(76%) 24/24	(100%) 294/396	(74%) 0.004
Anti-centromere	(%) 78/414	(19%) 2/18	(11%) 76/396	(19%) 0.55
Anti-topoisomerase	1	(%)	 86/416	(21%) 0/20	(0%) 86/396	(22%) 0.019
Internal Organ Involvement
Interstitial	lung	disease 156/429	(37%) 14/24	(58%) 142/396	(36%) 0.027
HRCT	fibrosis 185/364	(51%) 15/18	(83%) 170/346	(49%) 0.005
X-thorax	fibrosis 61/414	(15%) 6/20	(30%) 55/394	(14%) 0.096
TLC	≤	70%	of	predicted 71/273	(26%) 3/20	(15%) 68/253	(27%) 0.24
TLCO	≤	70%	of	predicted 276/363	(76%) 16/16	(100%) 260/347	(75%) 0.016
FEV1	≤	70%	of	predicted 98/385	(25%) 6/22	(27%) 92/363	(25%) 0.84
Diastolic	dysfunction	(cardiac	
US)
153/371	(41%) 7/19	(37%) 146/352	(42%) 0.69
PH	suspicion	by	cardiac	US 92/372	(25%) 3/20	(15%) 89/352	(25%) 0.43
PH	by	cardiac	catherization 57/187	(31%) 0/5	(0%) 57/182	(31%) 0.33
Renal Crisis 18/420	(4%) 1/24	(4%) 17/396	(4%) 1.0
SSc= systemic sclerosis; SSc-PM = Systemic sclerosis polymyositis overlap diagnosis; IQR = interquartile range; SSc= systemic 
sclerosis; HRCT = high-resolution computed tomography; TLC = total lung capacity of pulmonary function test; TLCO = Transfer 
Factor of the Lung for Carbon Monoxide US=ultrasonography; PH= pulmonary hypertension
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The mean (SD) age of all SSc patients at diagnosis was 50 (13.1) years, most patients were 
female (65%) and were classified as having the limited cutaneous subtype (73%) (Table 1). 
Baseline characteristics were similar between SSc-PM patients and SSc patients. However 
in 21% of the SSc-PM patients and in 41% of the SSc patients digital ulcers were present 
(Table 1). More than 95% of the patients were of Caucasian origin. The prevalence of the 
SSc-PM overlap in the Nijmegen Systemic Sclerosis cohort was 5.7%.
Serology and organ manifestations
SSc specific auto antibodies, namely anticentromere and antitopoisomerase 1, were present 
in 11% and 0% in the SSc-PM group and in 19% and 22% of the SSc patients (Table 1).
The presence of ILD was statistically significantly higher (58% vs. 36%) in the SSc-
PM overlap group compared to the non SSc-PM group (Table 1). Diastolic dysfunction 
on echocardiography was present in 37% of the SSc-PM group and in 42% of the SSc 
group. PH was diagnosed in none of the SSc-PM overlap patients and in 57 SSc patients. 
Regarding cardiac involvement and the presence of renal crisis there were no significant 
differences between SSc-PM and non SSc-PM group (Table 1). 
Myopathology
Analysis of all muscle biopsies (n = 24) revealed that necrotic muscle fibers and inflammation 
were the most prevalent features, occurring in 96% (n = 23) and 79% (n = 19) (Table 2). 
Furthermore, fibrosis was seen in 26% (n = 5) and presence of COX-negative fibers 30% (n = 
3) of the muscle biopsies. COX-negative fibers were present in patients over the age of 65 
years and therefore considered to be an effect of ageing. 
Table 2 | Myopathological markers of muscle biopsies slides
Characteristics No. SSc-PM patients
(n	=	24)
Necrotic	muscle	fibers 24 23	(96%)
Lymphocytic	infiltrates 24 15	(63%)
Positive MHC class I staining 12 11	(92%)
Inflammation* 24 19	(79%)
MAC° staining 10 5	(50%)
Fibrosis 19 5	(26%)
Presence	of	COX-negative	fibers 10 3	(30%)
Presence	of	CD8-positive	T-cells 12 8	(67%)
No. = number of patients; 
*Inflammation is defined as positive MHC class I staining or/and presence of  
lymphocytic infiltrates
° MAC: Membrane attack complex
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Survival
The frequency of death was 73 with 4127 person-year, resulting in a total mortality rate of 
1.77 deaths per 100 patient-years. The Kaplan-Meier survival curves of SSc-PM patients 
and SSc patients are shown in figure 1. For the SSc-PM overlap group the 5- and 10-year 
unadjusted cumulative survival from diagnosis were 82% and 68% compared to 93% and 
87% of the non SSc-PM group. Unadjusted survival was worse in the SSc-PM patients as 
compared to SSc patients (p = 0.017 log-rank test, Figure 1).
 
Figure 1 | Survival curve SSc vs. SSc-PM overlap
Cox-survival model with correction for confounders
The unadjusted and adjusted Cox analysis of the difference in survival between SSc-
PM and SSc patients are shown in Table 3. The model was adjusted for: gender, age at 
diagnosis, mRSS at diagnosis, SSc subtype (lcSSc/dcSSc).
According to both the unadjusted and the adjusted model, survival was significantly worse 
for SSc-PM patients in comparison to SSc patients (Table 3). In the unadjusted model the 
HR (95%CI) for SSc-PM overlap patients (versus SSc patients) was 2.40 (1.15-5.02). After 
adjusting for confounders the adjHR (95%CI) was 2.34 (1.09-5.02) indicating that SSc-PM 
was associated with a worse survival compared to SSc without PM, after controlling for 
gender, age at diagnosis, mRSS, SSc subtype. On graphical inspection (see methods) it 
appeared that the proportional hazard assumptions were not violated.
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Table 3 | Results of the Cox proportional hazard survival analysis
Characteristics β HR 95%	CI P-value
Unadjusted	model
SSc-PM	overlap	diagnosis 0.87 2.40 1.15-5.02 0.02
Adjusted	model
SSc-PM	overlap	diagnosis 0.85 2.34 1.09-5.02 0.029
Age at diagnosis 0.08 1.08 1.05-1.10 <	0.001
mRodnan skinscore 0.05 1.05 1.02-1.08 <	0.001
Diffuse	cutaneous	SSc	involvement 0.46 1.59 0.87-2.91 0.14
Male	sex 0.43 1.53 0.95-2.47 0.08
SSc-PM = Systemic sclerosis polymyositis overlap diagnosis; HR= hazard ratio
Sensitivity analyses
For the primary survival analysis, follow-up time since the first diagnosis was used. We 
also performed the analysis with different observation times defined as: patient-years 
since last diagnosis was confirmed (i.e. when both SSc and PM diagnosis were confirmed 
and an overlap diagnosis exist). Furthermore, we conducted the analysis with observation 
time since first non Raynaud complaints existed of patients. There were no differences; 
the unadjusted and adjusted model remained associated with a worse survival for SSc-PM 
patients. 
Causes of death
The total mortality was 33% in the SSc-PM overlap group, which was significant higher 
compared to the SSc patients where total mortality was 16% (Table 1). The causes of death 
in SSc-PM (n = 8) were: progressive heart disease (n = 2), myocardial infarction (n = 2), 
respiratory failure due to interstitial lung disease (ILD) (n = 1), sepsis (n = 2) and unknown 
cause (n = 1). Causes of death in the SSc group (n = 65) were progressive heart failure (n 
= 7), myocardial infarction (n = 2), respiratory failure due to ILD (n = 11) or pulmonary 
hypertension (n = 13), malignancies (n = 6), infections (n = 6) and other or unknown causes 
(n = 20). The most common cause of death among patient with SSc-PM overlap was 
cardiopulmonary involvement (63%), which was similar to the patients with SSc (51%).
Discussion
In this study we investigated whether SSc patients with an overlap syndrome with 
polymyositis have a worse survival compared to SSc patients without polymyositis. 
According to the results of this study, the SSc-PM overlap group showed a 5- and 10-
year cumulative survival from diagnosis of 82% and 68% compared to 93% and 87% of 
the SSc patients without PM. Univariate and multivariate survival analyses revealed 
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a worse survival for SSc-PM patients compared to SSc patients (adjHR (95%CI) 2.34 
(1.09-5.02)). The most common cause of death among patient with SSc-PM overlap was 
cardiopulmonary involvement (63%). 
The prevalence of SSc-PM overlap in our Nijmegen Systemic Sclerosis cohort was low 
(5.7%) compared to older investigations (3-7, 9). In more recent studies, prevalences of 
7.6% and 7.2% (12, 25) were observed, which is comparable to our finding. This discrepancy 
in prevalence compared to more dated studies can be explained by the different criteria 
used to define SSc myopathy and the different study designs. In our study we used strict 
criteria to select only inflammatory myopathies among SSc patient and not associated 
myopathies. The use of these strict criteria may have been insensitive to capture all SSc 
overlap PM cases. However, the criteria we used reflect daily clinical practice on which 
treating physicians consider invasive diagnostics such as muscle biopsies or EMG and 
diagnose by far the most PM overlap cases. 
A recent study of Jung et al. among patients of the Canadian Systemic Sclerosis cohort 
revealed that men, diffuse cutaneous SSc, anti-topoisomerase 1, anti-RNP and ILD was 
related to muscle involvement in SSc (14). These findings are in line with our result which 
also showed increased presence of men (46%) and ILD (58%) among the SSc-PM overlap 
group. Furthermore, a Kaplan-Meier analysis in the study of Jung et al. showed a worse 
survival for SSc patients with a increased serum CK. In addition, Hashimoto et al. found 
that overlap with myositis among Japanese patients with SSc was related to a poor 
prognosis (13). The results of Jung et al. and Hashimoto et al. confirm the finding of our 
study that SSc-PM is related with a worse survival for patients with SSc. Limitations of the 
study of Jung et al. are that no adjustment for confounders was applied for the survival 
analysis and inhomogeneous study population of patients was used ranging from patients 
with raised serum CK to patients with physician reported myopathy. 
A possible explanation for the poor prognosis for SSc-PM overlap patients is that SSc-
PM overlap could reflect a more active disease with increased presence of systemic 
complications. Previous studies and our results show an increased presence of pulmonary 
fibrosis and/or myocardial involvement in patients with SSc and a myopathy (7, 9, 12). 
Furthermore, the results of our study reveal that cardiopulmonary involvement is the most 
common cause of death. This should warrant physicians to perform regular screening for 
this complication and timely initiation therapy. One could argue if SSc-PM overlap patients 
could be potential candidates for stem cell transplantation, since promising results are 
found in patients with diffuse cutaneous SSc (26, 27). 
Limited studies are performed to assess specific immunosuppressive therapy among SSc 
patients with a myopathy (8, 28). Ranque et al. evaluated 35 SSc patient with a myopathy 
and found that the presence of histological muscle inflammation was associated with a 
good muscle prognosis within 3 months of treatment with corticosteroids (8). This result 
should lead treating physicians to consider performing a muscle biopsy to characterize the 
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possible myopathy. Furthermore, the results of Ranque et al indicate that corticosteroids 
should be part of the immunosuppressive therapy. 
The strength of our study is the large number of patients, the quality of clinical data and 
length of follow-up. The Nijmegen Systemic Sclerosis cohort represents the largest sample 
of patients with SSc in the Netherlands. The data are prospectively collected, with clinical 
features including information regarding modified Rodnan skin score, laboratory results, 
pulmonary function tests, echocardiography, HRCT, RHC and causes of death. Therefore, 
multivariate survival analysis could be performed with inclusion of major possible 
confounders. We also performed a sensitivity analysis with different observation time 
defined as: patient-years since last diagnosis was confirmed (i.e. when both SSc and PM 
diagnosis were confirmed and an overlap diagnosis exist). The outcome was not different, 
indicating that our results are robust regarding the worse survival for SSc-PM patients. A 
sensitive method was used to trace patients with clinical suspicion for polymyositis overlap 
among our SSc cohort (muscle complaints and a low threshold of 2 timer upper limit of 
serum CK). Moreover, muscle biopsy and EMG analysis were then used to diagnosis a 
polymyositis overlap creating a well-defined homogeneous group of patients with SSc-PM.
A limitation of our study is that all patients are selected from a single tertiary referral 
center which potentially could introduce a source of recruitment bias. Given these 
limitations, a comprehensive, multi-center database with longitudinal patient follow-up 
is necessary to fully validate our findings. The small sample size of SSc-PM overlap cohort 
makes us cautious for over-interpretation of results. Nonetheless, using strict criteria, we 
were able to identify a well-defined homogenous SSc-PM overlap cohort. Underdetection 
of cardiopulmonary involvement could have occurred, because not all patients underwent 
HRCT scans or echocardiography. However, we believe underdetection is limited in our 
study population, because unexplained dyspnea or decline in pulmonary function tests 
prompted treating physicians for further investigations. Observational studies inevitable 
face the occurrence of missing values. However, omitting patients with missing values 
from the analyses would be inefficient and might lead to bias (24). Therefore, missing 
values were imputed by multiple imputation such as the modified Rodnan skinscore. 
Unfortunately, no data concerning SSc-PM overlap associated antibodies were available, 
which can be regarded as a limitation to our study.
Conclusions
In conclusion, patients with SSc-PM overlap have a worse survival compared to patients 
with SSc. The most common cause of death among patients with SSc-PM overlap was 
cardiopulmonarycauses which was similar to the SSc group.These findings underline 
the need for regular screening on cardiopulmonary involvement in all SSc patients. 
Further research should focus on clinical trials to properly evaluate efficacy of different 
immunosuppressive therapy to improve survival for all SSc patients and especially 
patients with SSc-PM overlap.
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Abstract
Objective The diagnostic value of quantitative muscle ultrasound (QMUS) was assessed 
in patients suspected for an idiopathic inflammatory myopathy (IIM) and results were 
compared to electromyography (EMG).
Methods In 57 patients, suspected for IIM, panel diagnosis blinded for QMUS was used as 
reference standard. QMUS results were used to classify patients according an ultrasound 
neuromuscular disorder (NMD) algorithm (normal/borderline/abnormal). The predictive 
value of QMUS and EMG was assessed in a two by two table and a multivariate logistic 
regression model. 
Results Twenty-two patients (39%) were diagnosed with IIM; 8 polymyositis, 4 
dermatomyositis, 4 necrotizing myopathy, 3 inclusion body myositis and 3 non-specific 
myositis. Sixteen patients were classified with other NMD. We found an increased 
echointensity of the sternocleidomastoid, biceps, forearm flexor and tibialis anterior in 
the IIM group. Sensitivity, specificity, positive and negative predictive values (PPV/NPV) 
were 82%, 51%, 51%, 82% for ultrasound NMD algorithm and 63%, 64%, 50%, 75% for 
EMG. Multivariate analyses showed area under the curve (AUC) (0.81) (0.69-0.92) for 
ultrasound NMD algorithm, EMG (0.79) (0.67-0.92) and ultrasound NMD algorithm plus 
EMG (0.82) (0.70-0.93).
Conclusions QMUS with neuromuscular algorithm provides a similar diagnostic value 
compared to EMG for patients suspected of an IIM. QMUS could serve as a potential 
screening tool for clinicians to detect possible myopathies and to rule out the presence of 
IIM. Moreover, QMUS could be a non-invasive alternative for EMG if no disorders of the 
nervous system are expected.
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Introduction
The idiopathic inflammatory myopathies (IIM) form a large group of acquired myopathies. 
Unique clinical, histopathological, immunological and demographic features differentiate 
this group into three most common subsets: dermatomyositis (DM), polymyositis (PM) 
and sporadic inclusion body myositis (IBM) (1-3). Diagnosing IIM is clinically important, 
because unlike many other myopathies these disorders are potentially treatable (4).
The clinical diagnosis of IIM is based on the clinical presentation, elevation of creatine 
kinase (CK), together with electromyography (EMG) and muscle biopsy (1). However, EMG 
findings are not disease specific and are partly to rule out a neurogenic cause (5). Muscle 
biopsy with histopathological evaluation by experienced neuromuscular pathologist 
is central to diagnostic workup (1, 2, 6-8) False negative muscle biopsies by sampling error 
have been reported (6, 9-11). For these reasons muscle imaging has been suggested to be 
included in the diagnostic work up (12). Quantitative muscle ultrasound (QMUS) imaging 
has proven to be a useful, non-invasive technique to visualize normal and pathological 
skeletal muscle tissue including among patients with IIM (13-20). Previous studies suggest 
that active myositis during diagnosis is accompanied by a relative low echointensity and 
normal muscle size or slight swelling due to muscle edema (17, 21). In contrary, previous 
results of our research efforts in patients with juvenile dermatomyositis revealed 
increased echointensity with low to normal muscle thickness (18, 19). These findings indicate 
that QMUS could be useful for the diagnosis of IIM, however further validation is needed. 
Its availability, low cost and ease of examination may prove it to be a good non-invasive 
alternative for EMG in the diagnostic work up. In addition, muscle ultrasound could guide 
selection of muscle and location for biopsy and improve diagnostic accuracy of biopsy, 
which was previously shown in a MRI study (22).
In our current study we investigated the diagnostic accuracy of muscle ultrasound among 
patients suspected for the diagnosis of IIM. We also analyzed the predictive value of 
muscle ultrasound in comparison to EMG for the diagnosis of IIM.
Methods
Design
We retrospectively analyzed all referred patients for muscle ultrasound with suspicion 
for IIM at our tertiary neuromuscular centre from 19 April 2006 until 1 December 
2011 (Trial registration: www.trailregister.nl Identifier: NTR 2783). During this time 
period 886 patients underwent a muscle ultrasound as screening tool for the presence 
of neuromuscular disorder, 57 patients (6.4%) shared a suspicion for the diagnosis 
of IIM. Symptoms such as proximal muscle weakness, fatigue, skin rash and elevated 
muscle enzymes were the basis of suspecting an IIM. Besides ultrasound, patients 
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were diagnostically evaluated with EMG, biochemical tests and muscle biopsy when 
necessary. Histological evaluation of the muscle biopsies were performed by experienced 
neuromuscular pathologist. The choice of performing an EMG and/or muscle biopsy was 
at the discretion of the treating physician. Currently, no golden standard exists for the 
diagnosis of IIM. Therefore, we used a panel diagnosis as reference standard based on 
recommendations of Reitsma et al. (23). Results of muscle ultrasound were compared with 
the panel diagnosis to assess the diagnostic accuracy. After this, predictive value of muscle 
ultrasound was compared with EMG in a multivariate logistic regression model. We also 
performed a sensitivity analysis with replacement of the expert panel diagnosis with 
the muscle biopsy findings presence of IIM (yes/no) as golden standard. The study was 
approved by the regional ethics committee (Arnhem-Nijmegen, protocol nr 2010/469). 
We adhered to the Standard Reporting of Diagnostic Accuracy (STARD) criteria for design 
and adequate reporting of diagnostic studies (24). 
Ultrasound measurements
The images of participants had been made with IU22 Ultrasound device; Philips Healthcare, 
Best, The Netherlands, using a broad-band linear 5–17 MHz transducer. System settings 
were a gain of 70 dB, compression of 55, and focal zone 1–2.5 cm, and they were kept 
constant during the study. The method of ultrasound imaging was described in detail in a 
previous study by our group (25). Ultrasound measurement protocol consisted of minimum 
examination of four muscles, two proximal, two distal in both arms and legs (biceps 
brachii, forearm flexor, quadriceps femoris and tibialis anterior). The muscle echointensity 
(EI) was measured in three images taken of each muscle group.
Measurement of muscle echo intensity and muscle thickness
Analyses of the ultrasound images were performed offline with customized quantitative 
image analysis software (Qumia). In each muscle a region of interest was selected 
including as much muscle as possible. The mean EI was calculated from this region and 
averaged over the three measurements. EI was corrected for age, sex and handedness. EI 
measurements were transformed into z-scores (number of standard deviations differ from 
average of healthy subjects). 
Previous reported ROC-analyses revealed optimal cut-off points regarding muscle EI for 
the presence of neuromuscular disease (NMD) (26, 27).
Ultrasound NMD algorithm
–  Abnormal: EI above 3.5 SD in one muscle or 2.5 SD in two muscles or 1.5 SD in three 
muscles. Patients with age of 65 years or older, three muscles with EI above 2 SD 
(measurement of six or more muscles).
–  Borderline: EI between 2.0 and 2.5 SD in one muscle or above 1.5 SD in two muscles 
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(measurement of less than six muscles) or above 1.0 SD in three muscle (measurement 
of less than six muscles). Patients with age of 65 years or older, EI above 2.5 SD in one 
muscle (measurement of less than six muscles) or 3.0 SD in one muscle (measurement 
of six or more muscles).
– Normal: not fulfilling criteria for abnormal or borderline regarding EI. 
Panel diagnosis
The panel consisted of two rheumatologists (F.H. and R.C.) and a neurologist (A.V.) all 
experienced in diagnosis and treatment of IIM patients. Their panel diagnosis were 
based on written cases of the patients which included history of the patient, physical 
examination, lab results, EMG and muscle biopsies findings. The panel members evaluated 
whether a neuromuscular disease (NMD) and IIM were present or not. Two primary panel 
members, F.H. and A.V., diagnosed each case separately. In case of disagreement both 
panel members reevaluated their diagnosis and tried to reach consensus during a meeting. 
When no consensus was reached the third panel member (R.C.) was asked to provide a 
final diagnosis. All panel members were blinded for results of muscle ultrasound. The 
panel members used their clinical expertise and ENMC classification criteria to come to 
a diagnosis (2). 
EMG
Results of available EMG were quantified per muscle regarding denervation, polyphasic 
units and patterns. Furthermore, existing qualitative EMG reports were used to classify 
EMG into presence for myopathic changes (negative/borderline/positive). The ‘classical 
triad’ of EMG findings in DM and PM is defined as a combination of short, small, polyphasic 
motor unit potentials (MUPs), fibrillations and positive sharp waves, and complex 
repetitive discharges (CRDs) (5).
Statistical analysis
Patient characteristics QMUS, EMG and muscle biopsies characteristics were compared 
with a one-way ANOVA, Krukal-Wallis, one sample T-test, χ2 or Fisher exact test. Statistical 
significance was defined as p-value of < 0.05. To evaluate interobserver reliability between 
F.H. and A.V. in judging the written cases on presence of IIM, the Cohen κ was calculated 
on the results reached before the consensus meeting.
Using a two by two table, sensitivity, specificity, positive and negative predicting values of 
ultrasound NMD algorithm and EMG with myopathic findings for the presence of IIM were 
calculated. Univariate logistic regression with dependant variable presences of IIM was 
used to assess separate relevant predictors age, serum CK, ultrasound NMD algorithm and 
EMG. Multivariate logistic regression analysis was used to compare the predictive value 
of muscle ultrasound with EMG for the presence IIM. We developed 3 models: model A 
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consisting of ultrasound predictor NMD algorithm, model B consisting of predictor EMG 
with myopathic results and model C consisting of ultrasound NDM algorithm and EMG 
predictor. Comparison of discriminative ability of the different models was assessed with 
receiver operating curves (ROC) providing Area Under the Curve (AUC), sensitivity and 
specificity. 
Multiple imputation was used for missing values regarding confounder EMG used in the 
multivariate logistic regression model using QMUS, EMG, diagnosis for IIM, muscle biopsy, 
serum CK, ANA, ENA as predictors. Furthermore, missing values of muscle biopsy (sign’s 
of IIM) were also imputed. Multiple imputation was carried out with a linear regression 
method with a random component, conditionally on data being missing at random and 
calculated based on 20 imputed datasets. (28). During diagnosis EMG and muscle biopsy 
results were missing in 9% and 16% of the patients. Missing value analysis showed no 
abnormal pattern. All statistical analysis were performed with SPSS package version 23 
(IBM Inc., New York, USA). 
Results 
Patients and characteristics
After diagnostic evaluation of the 57 patients, 22 patients (55% female, 59.1 years mean 
age) were diagnosed by the expert panel with a IIM, 8 polymyositis, 4 dermatomyositis, 4 
necrotizing myopathy, 3 inclusion body myositis and 3 non-specific myositis (see Table 1 and 
Figure 1). Among the non-IIM diagnosed patients, 16 patients (63% female, 53 years mean 
age) were classified with other neuromuscular disorders, 5 undifferentiated myopathy, 
2 mitochondrial myopathy, 2 axonal sensorimotor polyneuropathy, 1 RYR1 congenital 
myopathy, 1 myofibrillar myopathy, 1 chronic inflammatory demyelinating polyneuropathy, 
1 probable amyotrophic lateral sclerosis (ALS), 1 Lambert Eaton myasthenic syndrome 
(LEMS), 1 Limb-girdle muscular dystrophy 1B and 1 possible facioscapulohumeral muscular 
dystrophy (FSHD). No diagnosis was made for 19 patients (42% female, 53.5 years mean 
age). Significant increased serum CK with median of 975 U/L (IQR 248-2330) and increased 
presence of positive ANA was found among the patients with IIM compared to the other 
groups. The IIM group showed four patients (18%) with anti-Jo1, tree patients (13%) with 
anti-SSA antibodies and tree patients (13%) with anti-RNP, 27 patients were not tested for 
these antibodies. No other myositis specific or associated antibodies were tested. 
Reliability of primary panel members
The measurement of agreement of the two primary panel members (F.H. and A.V.) for the 
presence of IIM measured as Cohen κ was 0.76; the percentage of agreement was 89%. 
Three cases needed evaluation by the third panel member (R.C.). 
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Table 1 | Study population characteristics
Figure 1 | Flow chart study population
Characteristics IIM diagnosis by 
expert	consensus
(n	=	22	)
NMD	(not	IIM)
(n	=	16)
No diagnosis
(n	=	19)
Significance
(p-value)
Age	mean	in	years	(SD) 59.1 (14.4) 53.0 (14.9) 53.5 (12.3) 0.21
Sex	(male/female) 10/12 6/10 11/8 0.47
Median	duration	of	complaints	before	
diagnosis (months)
12 (7-27) 21 (8-99) 18 (5-48) 0.42
Serum	CK	median	(IQR)	U/L 975 (248-2330) 245 (106-481) 128 (56-165) 0.00
Proportion	Serum	CK	>	2	x	upper	limit	(%) 15/21	(71%) 5/14	(36%) 1/18	(6%) 0.00
ANA	positive	(positive/available) 12/16	(75%) 2/6	(33%) 3/13	(23%) 0.01
Anti-Jo1 4/15	(27%) 0/5 0/10 0.14
Anti-SSA 3/15	(20%) 0/5 0/10 0.26
Anti-SSB 1/15	(7%) 0/5 0/10 1.00
Anti-RNP 3/15	(20%) 0/5 0/10 0.26
Anti-dsDNA 2/4	(50%) NA NA NA
Anti-SM 1/15	(7%) 0/5 0/10 1.00
Anti-cardiolipine 1/1 NA NA NA
Cryoglobuline	type	3 1/1 NA NA NA
Available EMG 19/22	(86%) 15/16	(94%) 18/19	(95%) 0.72
Available	muscle	biopsy 20/22	(91%) 13/16	(81%) 15/19	(79%) 0.59
IIM: idiopathic inflammatory myopathy; NMD: neuromuscular disorder; SD: standard devation; IQR: interquartile range; 
NA: not available; EMG: electromyography
Available patients with suspicion for neuromuscular 
disease all screened with muscle ultrasound n = 886
patients suspected of diagnosis IIM n = 57
Patients	with	IIM	n = 22
– Available EMG 19/22 (86%)
– Available muscle biopsies 20/22 (91%)
Patients	with	other	NMD	n	=	16
– Available EMG 15/16 (94%)
– Available muscle biopsies 13/16 (81%)
Patients	with	non-IIM	n	=	35
– Available EMG 33/35 (94%)
– Available muscle biopsies 28/35 (80%)
Patients	with	no	diagnosis	n = 19
– Available EMG 18/19 (95%)
– Available muscle biopsies 15/19 (79%)
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Muscle ultrasound echointensity
The EI of the sternocleidomastoid, biceps brachii, forearm flexor and tibialis anterior 
muscles was significantly increased in the IIM group compared to healthy controls. In 
addition the forearm flexor muscles revealed a significant increased median EI 3.0 (2.3-
3.9) compared to the NMD and no diagnosis group. The other muscles groups showed no 
significant difference between IIM patients and the other groups.
Table 2 | Muscle ultrasound, electromyography and muscle biopsy findings
In the IIM group, 16 patients (73%) showed affected proximal muscles (EI z-score ≥ 2) 
compared to 10 patients (63%) NMD group and 10 patients (53%) in no diagnosis group. 
In the majority of these patients proximal arm muscles were affected; 11 patients (50%) 
IIM group, nine patients (60%) NMD group and nine patients (41%) in the no diagnosis 
Characteristics IIM 
(n	=	22)
NMD	(not	IIM)
(n	=	16)
No diagnosis
(n	=	19)
Significance	
(p-value)
Muscle Echointensity median (IQR)
Sternocleidomastoid 1.75	(0.83-2.9)* 1.86 (-0.35-3.75) 1.3	(0.65-1.85)* 0.65
Biceps	brachii 1.99	(1.22-2.85)* 2.4	(0.84-3.0)* 1.95	(0.68-2.3)* 0.60
Forearm	flexor	 3.05	(2.34-3.92)*	 2.4	(1.92-3.32)* 1.73	(1.3-2.8)* 0.01
Forearm	extensor 1.45 (0.6-3.27) 3.6 (NA) 2.71	(1.63-3.1)* 0.30
Rectus	femoris	 0.6 (-1.05-2.65) 0.6 ((-1.8-1.2) 0.3 (-1.0-0.97) 0.12
Tibialis anterior 1.7	(1.17-2.52)*	 1.6	(1.03-2.85)* 1.2	(0.4-1.69)* 0.11
Number of patients with ultrasound+
0	affected	proximal	muscles 6/22	(27%) 6/16	(38%) 9/19	(47%) 0.32
1-2	affected	proximal	muscles 12/22	(55%) 9/16	(56%) 10/19	(53%) 0.32
>	2	affected	proximal	muscles 4/22	(18%) 1/16	(6%) 0/19	(0%) 0.32
Number	of	patients	with	ultra-
sound:	+
0	affected	distal	muscles 3/22	(14%) 3/16	(19%) 8/19	(42%) 0.27
1-2	affected	distal	muscles 14/22	(64%) 8/16	(50%) 8/19	(42% 0.27
>	2	affected	distal	muscles 5/22	(23%) 5/16	(31%) 3/19	(16%) 0.27
Ultrasound NMD pattern 
Normal	ultrasound	 2/22	(9%) 4/16	(25%) 6/19	(32%) 0.05
Borderline	NMD	presence 2/22	(9%) 2/16	(13%) 6/19 (32) 0.05
NMD	pattern 18/22	(82%) 10/16	(63%) 7/19	(37%)	 0.05
EMG qualitative report
No	myopathic	findings	 6/19	(32%) 7/15	(47%) 10/18	(56%) 0.27
Borderline	findings 1/19	(5%) 1/15	(7%) 3/18	(17%) 0.27
Positive	myopathic	findings 12/19	(63%) 7/15	(47%) 5/18	(28%) 0.27
Muscle biopsy
Biopsy	with	myopathic	results 19/20	(95%) 9/13	(69%) 4/15	(27%) 0.00
Biopsy	with	sign’s	of	IIM 19/20	(95%) 0/13 0/15 0.00
IIM: idiopathic inflammatory myopathy; NMD: neuromuscular disorder; IQR: interquartile range; SD: standard 
deviation; *: significant different to normal (z-score = 0); +: affected muscle is defined as an echointensity with a z-score ≥ 
2; EMG: electromyography
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group. Significantly higher number of patients with affected proximal leg muscles were 
observed in the IIM group seven patients (33%) compared to one patient in both NMD 
and no diagnosis group. No significant differences were seen in comparing patients with 
affected proximal arm, neck muscles or pattern of proximal arm, leg and/or neck muscles 
between the groups (see Table 2). Presence of positive ultrasound findings according to 
NMD algorithm were found 18 patients (82%) IIM group, 10 patients (63%) NMD group 
and seven patients (37%) in no diagnosis group.
Patients diagnosed with IIM showed a total mean echointensity z-score of 5.1 (4.4) of all 
measured proximal muscles compared to 4.3 (5.4) NMD (other than IIM) group and 1.7 
(4.7) no diagnosis group.
Electromyography
Among the IIM group 12 patients (63%) revealed myopathic EMG findings, seven patients 
(47%) in the NMD group and 5 patients (28%) in the no diagnosis group (see Table 2). 
Numbers of affected proximal or distal muscles showed no differences. On EMG analyses 
the most affected proximal muscles were arm muscles; 13 patient (68%) followed by the 
leg muscles in 10 patients (53%) in the IIM group. Furthermore, the most observed EMG 
pattern among 10 patients with IIM (53%) was small polyphasic units and spontaneous 
activity.
Muscle ultrasound and EMG
The sensitivity and specificity of ultrasound NMD algorithm and EMG for the presence 
of IIM were 82%/51% and 63%/64% (see Table 3). The positive predictive values (PPV) 
of NMD algorithm and EMG of for the presence of IIM were 51% and 50%; the negative 
predictive value (NPV) were 82% and 75%. The PPV of ultrasound NMD algorithm and 
EMG for the presence of NMD were 80% and 79%; the negative predictive value (NPV) 
were 55% and 46%.
Table 3 | Diagnostic value of muscle ultrasound and EMG
Characteristics IIM 
(n	=	22)
No IIM diagnosis
(n	=	35)
Total Diagnostics
Ultrasound NMD pattern*
Normal	ultrasound	 4 18 22 Sensitivity:	82%
NMD	pattern 18 17 35 Specificity:	51%
Total 22 35 PPV:	51%/NPV:	82%
EMG qualitative report*
No	myopathic	findings	 7 21 28 Sensitivity:	63%
Positive	myopathic	findings 12 12 24 Specificity:	64%
Total 19 33 PPV:	50%/NPV:	75%
* Borderline ultrasound NMD presence and EMG findings were considered as normal ultrasound or no 
myopathic findings EMG IIM: idiopathic inflammatory myopathy; NMD: neuromuscular disorder;  
PPV: positive predictive value; NPV: negative predictive value; EMG: electromyography
CHAPTER 5
76
Univariate analysis regarding the presence of IIM revealed an odds ratio (OR) of 3.00 
(95% confidence interval) (0.83-10.75) for age ≥ 50 years, OR 10.83 (2.95-39.66) for 
serum CK ≥ 2x upper limit, OR 5.29 (1.01-27.74) for ultrasound NMD algorithm and OR 
2.44 (0.72-8.26) for EMG with myopathic findings (see Supplementary file Table 5). The 
multivariate model A consisted of ultrasound NMD algorithm, age and serum CK, yielding 
an AUC of 0.81 (0.69-0.92) with sensitivity of 70% and specificity of 80% (see Table 4). In 
the multivariate model B NMD algorithm was replaced by EMG and showed an AUC of 
0.79 (0.67-0.92) with sensitivity of 73% and specificity of 79%. Model C consisted of both 
ultrasound NMD algorithm and EMG revealing the highest AUC of 0.82 with sensitivity of 
76% and specificity of 76%. We also performed a sensitivity analysis with replacement of 
the dependant variable presence of IIM by expert panel diagnosis with the variable muscle 
biopsy presence of IIM (yes/no) and chart based diagnosis IIM (yes/no). Similar results 
were found in comparison with the primary analysis.
Table 4 | Multivariate logistic analysis: results in odds ratio
Predictor Model A Model B Model C
Age	>	=	50	year 2.97 (0.65-13.59) 2.88 (0.62-13.28) 2.98 (0.62-14.21)
Serum	CK	>	=	2x	upper	limit 7.52 (1.57-36) 8.76 (1.55-49.55) 7.35 (1.22-44.21)
Muscle ultrasound
Total	echointensity	of	proximal	muscles/
measured	muscle
Total	number	of	affected	proximal	muscles
Distal	muscles	affected	(yes/no)
NMD	algorithm:
- No NMD Reference Reference
-Borderline	presence	of	NMD	(yes/no) 1.61 (0.13-18.87) 1.62 (0.13-19.57)
-Presence	of	NMD	(yes/no) 3.01 (0.44-20.55) 3.01 (0.43-21.09)
EMG qualitative report
Negative	myopathic	results Reference Reference
Borderline	myopathic	results 1.00 (0.08-11.67) 0.94 (0.07-12.09)
Positive	myopathic	results 1.28 (0.23-7.13) 1.03 (0.17-6.04)
Cox	&	Snell	R	square 0.28 0.26 0.28
Nagelkerke	R	square 0.38 0.35 0.38
Hosmer Lemeshow Test 0.91 0.94 0.69
AUC	(95%	CI) 0.81 (0.69-0.92) 0.79 (0.67-0.92) 0.82 (0.70-0.93)
Sensitivity/specificity	(best	cutt-off) 70%/80% 73%/79% 76%/76%
Model A: Age, serum CK, NMD algorithm
Model B: Age, serum CK, EMG 
Model C: Age, serum CK, NMD algorithm, EMG
NMD: Neuromuscular disorder; IIM: idiopathic inflammatory myopathy; EMG: elektromyography AUC: area 
under the curve of ROC analysis; 95% CI: 95% confidence interval
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Discussion
The aim of this study was to assess the diagnostic value of quantitative muscle ultrasound 
for patients with a suspicion for the presence of idiopathic inflammatory myopathy 
and compare results with electromyography. We found an increased EI of the proximal 
muscles: sternocleidomastoid, biceps and the distal muscles: forearm flexor and tibialis 
anterior. The majority of the IIM patients revealed at least one affected proximal muscle. 
QMUS with neuromuscular algorithm provided a similar diagnostic value compared to 
EMG for patients suspected of an IIM. Combining QMUS and EMG did not significantly 
improve the diagnostic accuracy. 
Increased EI has shown to be caused by increased amount of intramuscular fibrous and 
fatty infiltration (29, 30). However, in early states of IIM only little fibrosis is present, which 
might imply that inflammation itself could also cause increased muscle EI. Earlier studies 
have argued that muscle EI is normal or decreased in the acute phase of IIM due to edema 
(17, 21). The results of the present study could not confirm this hypothesis: we found a 
significantly increased EI at diagnosis. Future studies with power doppler (PD) or contrast-
enhanced PD could be used to assess hypervascularization and help to differentiate 
between acute inflammation and structural muscle changes. Previous studies with PD and 
contrast-enhanced PD showed a valuable addition to the diagnostic workup of IIM with 
sensitivity/specificity of 73%/91% for contrast-enhanced PD (31, 32). 
QMUS is limited in the ability to properly differentiate between IIM and other NMDs, 
since an increased EI can reflect different structural muscle changes as described above. 
The strength of QMUS lays in the ability to differentiate between healthy muscle tissue 
and affected muscles. Surprisingly, the clinically most affected muscle, the rectus femoris, 
showed the least increase of EI at diagnosis. A possible explanation could be that edema or 
elevated blood flow decreased muscle EI.
Reimers et al evaluated muscle ultrasound among 70 adult patients with histological 
proven IIM (17). Chronic IIM yielded higher echointensity and more atrophy than acute 
disease. Acute IIM often presented with lower echointensity and muscle edema. The 
sensitivity of muscle ultrasound in detecting histological proven disease was 82.9%, with 
a specificity of 97.1%. The selection of patients was solely based on already histological 
proven diagnosis of IIM and controls consisted of 102 healthy participants. For this reason, 
the reported diagnostic value of muscle ultrasound is probably biased.
Currently, most sensitive way to detect muscle edema in IIM is inversion recovery 
magnetic imaging (STIR or TIRM MRI) with a sensitivity in active myositis of about 80–90% 
(33, 34). The main disadvantages of MRI are its cost, availability and the necessity of sedation 
or anesthesia in children, whereas ultrasound can be done at bedside within 15 minutes.
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Since no golden standard reference test for the diagnosis IIM exists, we used an expert 
panel blinded for the QMUS results to make a consensus diagnosis. We also performed a 
sensitivity analysis with replacement of expert panel diagnosis as reference test by muscle 
biopsy outcome and chart diagnosis. The outcome was similar, indicating that our results 
are robust regarding the diagnostic value of muscle ultrasound for the presence of IIM 
among suspected patients. Additionally, all patients during 2006-2011 with a suspicion 
for IIM and an available muscle ultrasound were included leading to a heterogenic case-
mix of patients with high, low or intermediate suspicion of IIM. In this way, the diagnostic 
value of muscle ultrasound is properly assessed and is the risk for spectrum bias effects 
minimized (24). 
The present study has several limitations. Only patients who underwent a muscle 
ultrasound were retrospectively selected. The majority of these patients were referred for 
muscle ultrasound by a treating neurologist. In addition, patients were only selected from 
our tertiary referral center, causing possible recruitment bias. Myositis specific antibodies 
play an important role in the diagnosis of IIM. Unfortunately, these serological markers 
were limited available in our study. We inevitable faced the occurrence of missing values 
of reference tests EMG and muscle biopsies due to the invasive nature of the tests and 
awareness of the outcome of muscle ultrasound for treating physician which probably 
guided further diagnostics (i.e. partial verification). When only participants who received 
all the reference tests were included in the analysis (complete case analysis) results might 
be biased. (35). Therefore, missing values were imputed by multiple imputations to prevent 
partial verification bias (28, 35, 36). 
Conclusions
In conclusion, QMUS with neuromuscular algorithm provides a similar diagnostic value 
compared to electromyography for patients suspected of an idiopathic inflammatory 
myopathy with a low rate of false negative results. QMUS could serve as a potential 
screening tool for clinicians to detect possible myopathies and to rule out the presence of 
IIM. Moreover, QMUS could be a non-invasive alternative for EMG if no disorders of the 
nervous system are expected. 
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Supplementary	Table	5	| Univariate analysis of predictor for diagnosis of IIM
Predictor Odds ratio 95%	CI Significance	
(p-value)
Age	>=	50	years 3.00 0.83-10.75 0.09
Male	sex 1.13 0.38-3.30 0.81
Serum	CK	>	=	2x	upper	limit 10.83 2.95-39.66 0.00
Ultrasound
NMD algorithm
-	Negative	for	presence	NMD Reference
-	Borderline	presence	of	NMD	 1.25 0.14-10.94 0.84
-	Presence	of	NMD	 5.29 1.01-27.74 0.04
EMG qualitative report
Negative	myopathic	results Reference
Borderline	myopathic	results 0.86 0.08-8.73 0.89
Positive	myopathic	results 2.44 0.72-8.26 0.14
Muscle biopsy
Biopsy	with	sign’s	of	IIM	(yes/no) 163.92 5.74-4674.16 0.00
IIM: idiopathic inflammatory myopathy; NMD: neuromuscular disorder; EMG: electromyography
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CHAPTER 6
Increased fascial thickness of the 
deltoid muscle in dermatomyositis 
and polymyositis: An ultrasound study
 
K.J. Bhansing, M.H. van Rosmalen, B.G.M. van Engelen, M.C. Vonk, P.L.C.M. van Riel, 
S. Pillen
Muscle Nerve. 2015;52:534-9.
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Abstract
Objective We investigated the use of ultrasound to detect fascial thickening in 
dermatomyositis (DM) and polymyositis (PM) of the deltoid, vastus lateralis (VL), and 
rectus femoris (RF) muscles.
Methods Fascial thickness of 7 DM and 5 PM patients was compared to healthy controls 
(n = 54). 
Results The deltoid fascia thickness was two-fold thicker in the DM/PM group (1.15 mm vs. 
0.54 mm; P < 0.001) compared to healthy controls. Eight patients had markedly thickened 
deltoid fascia (> 5 SD). Only 1 patient with a mild clinical presentation had normal deltoid 
fascia thickness. Four patients also had fascial thickening of the VL and/or RF.
Conclusions Deltoid fascia thickness was increased significantly in DM and PM patients, 
while the quadriceps muscle only showed thickened fascia in severely affected patients. 
This study suggests that a concomitant fasciitis might be present more often than 
previously thought. 
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Introduction
Dermatomyositis (DM) and polymyositis (PM) belong to the heterogeneous group of the 
idiopathic inflammatory myopathies (IIM) and have in common the presence of moderate 
to severe muscle weakness due to inflammation of predominantly proximal skeletal 
muscles (1, 2). In DM the inflammation is perivascular or at the periphery of the fascicle 
and is often associated with perifasicular atrophy (3, 4). In contrast, PM is characterized by 
inflammation of multiple foci within endomysial parenchyma and consists predominantly 
of CD8+T-cells that invade healthy muscle fibers (1, 2). 
Several studies provide evidence that not only the muscle fibers are affected in DM, 
but also the fascia is affected (5-9). In 2 studies abnormal hyperintensity of the fascia on 
magnetic resonance imaging (MRI) was found, indicative of a concomitant fasciitis, which 
was confirmed with biopsies in 1 study (5, 6). Furthermore, 2 case reports described that 
even amyopathic DM can be accompanied by biopsy-proven fasciitis (7, 8). It was speculated 
that fasciitis might be a marker for an early disease phase in DM (6, 8). In PM a concomitant 
fasciitis has not been reported.
Ultrasonography (US) is an easily accessible, inexpensive, and non-invasive tool to detect 
structural muscle changes caused by neuromuscular diseases (10). In addition, muscle 
ultrasound can detect fascial thickening, which can indicate the presence of a fasciitis, as 
described in a case report of a child with eosinophilic fasciitis (11). 
In this cross-sectional exploratory study we investigated whether fascial involvement in 
idiopathic inflammatory myopathies can be determined objectively by ultrasound. 
Methods
Participants 
IIM group: Twelve patients with probable or definite IIM (DM, n = 7; PM, n = 5), diagnosed 
by a rheumatologist according to the Bohan and Peter criteria (12, 13), were recruited from 
the Rheumatology department of Radboud University Medical Center, from February 
2011 until June 2012. The patients were recruited consecutively as a part of an ongoing 
study to determine the value of muscle ultrasound as a disease activity tool. Demographic, 
clinical, and ultrasound parameters were collected in the IIM patients. Clinical features 
included disease duration, type of IIM, serology, serum CK level within 1 week of 
ultrasound assessment, presence of pulmonary fibrosis on HR-CT scan, muscle biopsy 
findings at diagnosis, medication history, and functional disability. Functional disability 
was measured among the IIM patients by the validated Dutch version of the Health 
Assessment Questionnaire Disability Index (HAQ-DI) on a scale from 0 to 3 in which a 
higher score signifies more disability (14, 15) 
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Control group: The control group consisted of 54 healthy volunteers (27 men and 27 
women, ages 21–86 years) who had previously been enrolled in a study describing 
reference values of echo intensity and muscle thickness for several muscles (16).
Equipment
IIM patients were measured with the Z. one ultrasound device with a broad-band linear 
10-5 MHz transducer (Zonare Medical Systems, Mountain View, USA). System parameters 
were set at a gain of 78 dB, compression of 60, and greymap M3/P0. The images of the 
healthy volunteers had been made with IU22 Ultrasound device; Philips Healthcare, Best, 
The Netherlands, using a broad-band linear 5–17 MHz transducer. System settings were 
a gain of 70 dB, compression of 55, and focal zone 1–2.5 cm, and they were kept constant 
during the study. A depth setting of 4 cm was used to collect images of the deltoid and 6 
cm for the VL and RF with both devices.
Analyses of the ultrasound images were performed offline with customized quantitative 
image analysis software (Qumia) with caliper function. Test-retest measurements in 
6 healthy volunteers revealed no systematic bias in measurement of fascia thickness 
between both ultrasound devices. 
Study protocol
As IIM mostly affects proximal muscles, we chose to examine the deltoid, vastus lateralis 
(VL), and rectus femoris (RF) muscles. All subjects were examined in the supine position 
with the arms and legs extended and the muscles completely relaxed. A generous amount 
of contact gel was used to minimize transducer pressure on the skin. The deltoid muscle 
(middle part) was measured a quarter of the distance from acromion to lateral epicondyle; 
the VL was measured two-thirds of the distance from the anterior superior iliac spine to 
the upper edge of the patella; the RF was measured half the distance between anterior 
superior iliac spine to the upper edge of the patella. This standard transducer location 
corresponded to the largest diameters of the individual muscle bellies. Muscle thickness 
was determined as described previously (17).
Measurement of fascia thickness
In this study, the fascia is defined as a sheath or any number of other dissectible 
aggregations of connective tissue which envelops the muscles. This definition is in 
accordance with the proposed refinement of the edition of Terminologia Anatomica of the 
deep fascia (18). 
As the fascia is relatively thin, a 2-fold magnification was applied (Figure 1). Calipers were 
placed at an interval of 0.25 cm with a maximum of 12 calipers per scan. Fewer calipers 
were placed when the length of the fascia was not totally visible. If less than 3 calipers 
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could be placed or the fascia was not easily perceptible, the image was not included in 
the analysis. The fascia which lay between subcutaneous tissue and muscle was defined 
as superficial fascia and fascia between muscle and underlying muscle as deep fascia. All 
measurements were performed by the same observer (M.v.R). To determine intra- and 
interobserver agreement, 25 images (control group: 15 images, IIM group 10 images) 
were analyzed twice, and a second observer also analyzed them (K.B.). As the patients and 
healthy controls were made with 2 different ultrasound devices, the observers could not 
be blinded to the diagnosis of IIM or healthy control. 
 
Figure 1| Transverse ultrasound images of deltoid muscle of healthy person and IIM patient
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Statistical analysis
Reliability
The reliability of the fascia thickness measurement method was evaluated with the 
intraclass correlation coefficient (ICC), a 2-way model with absolute agreement. We 
assessed the ICC for 5 different measurement protocols: the mean of all measurements 
within an image (with a 0.25 cm interval), the mean of measurements with a 0.5 cm 
interval, with a 1 cm interval, the mean of the 3 thickest measurements of each image, and 
the 6 thickest measurements of each image. The intraobserver ICC and interobserver ICC 
were determined for the 3 muscles separately and the different measurement protocols. 
ICC values with a minimum of 0.70 are considered acceptable for newly developed scales 
which are used for group comparison (19).
Reference values 
Multiple linear regression with a stepwise backward selection was applied to the 
measurements of the control group to indentify whether age, gender, height, weight, 
muscle thickness, and echointensity of the investigated muscle affected the reference 
values. We regarded 1 healthy control with a weight of 41 kg as an outlier and therefore 
discarded this control from the regression analysis. 
Fascia	thickness	in	healthy	controls	compared	to	patients	with	IIM	
An independent samples t-test was used to compare the mean fascia thickness of the 
normal reference values and IIM patients for the different measurement protocols. 
Furthermore the amount of patients with increased fascia thickness (defined as > 2 SD 
above normal) was described.
Clinical and ultrasound characteristics
The fascia thickness was correlated with all clinical data and muscle thickness using Pearson 
correlations or Spearman rho correlation coefficients in case of numerical data or Chi-
square and the Fisher exact test for nominal data. Statistical analyses were performed with 
SPSS version 20 (IBM Inc., Chicago, USA). Statistical significance was defined as P <0.05. 
Results
Participants
A total of 27 women and 27 men were included as healthy participants, median age 52 
years (range 21-86). 
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The IIM group consisted of 8 women and 4 men, median age 44 years (range 18-64), (see 
Table S1, available online). Seven patients were diagnosed with DM and 5 with PM. The 
median disease duration was 3.4 years (range 0-23). Four patients had been symptomatic 
<1 year. Five patients were in clinical remission (42%), and 7 (58%) had active disease. The 
median HAQ-DI was 1.13 (range 0-2.13). Muscle thickness was decreased, with a mean SD 
score of -1.2 (1.3 SD) deltoid, -1.0 (1.2 SD) RF muscle, and -1.2 (1.0 SD) VL muscle. Disease 
duration, serum CK, and HAQ-DI scores were not significantly different in DM compared 
to PM patients. 
Fascia thickness in healthy controls
All but 1 measurement contained at least 3 caliper pair placements, but the majority 
of measurements contained ≥ 6 caliper pair placements to determine fascia thickness 
(deltoid: 94.4%; VL superficial: 98.1%, VL deep: 68.5%; RF superficial: 92.6%; and RF 
deep: 75.9%). The fascia of the deltoid appeared to be 2 times thinner in almost all cases 
compared to the superficial and deep fasciae of the VL and RF (0.54 mm vs. 1.28, 1.33, 
1.02, 1.23 mm) (Table 2).
Multiple linear regression was used to identify potential confounders (age, gender, 
height, weight, muscle thickness, and echointensity) which affected the fascia thickness 
of the different muscles among the healthy controls. Weight was found to be a significant 
predictor of deep fascia thickness of the VL and RF. However, the adjusted R2 was < 0.15 
in both cases. Since we found a low adjusted R2 and the association between weight and 
fascia thickness in only 2 of the 4 fasciae, we decided that no correction for weight was 
needed.
 Reliability
The measurement protocols of 0.25 cm, 3 thickest measurements, and 6 thickest 
measurements demonstrated an acceptable intraobserver and interobserver reliability 
(ICC > 0.7) in at least 3 of 5 fasciae (Table 1). The 0.25 cm measurement protocol showed 
the highest mean intra- and interobserver ICC value of 0.76 and 0.77. 
Fascia thickness in IIM patients
The fascia could be identified easily in most IIM patients. The deltoid fascia of the IIM 
patients was less echogenic (i.e. more greyish) on the ultrasound images compared to the 
healthy controls (Figure 2). When scanning, it became clear that the thickening pattern 
of the deltoid fascia was inhomogeneous (Figure 1). Measurements were made at the 
previously determined fixed location to be able to compare them to the healthy controls. 
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Table 1 | Intra- and interobserver ICC of the different measurement protocols
Muscles ICC Number* 0.25	
cm
0.5	
cm
1 
cm
3 thickest 
measurements
6	thickest	
measurements
Deltoid (intra) 15/9 0.93 0.69 0.48 0.79 0.80
(inter) 15/9 0.87 0.65 0.71 0.72 0.72
Superficial	VL (intra) 15/10 0.68 0.55 0.61 0.72 0.67
(inter) 15/10 0.91 0.87 0.85 0.87 0.90
Deep	VL (intra) 15/8 0.77 0.62 0.66 0.73 0.74
(inter) 15/8 0.73 0.70 0.51 0.73 0.74
Superficial	RF (intra) 15/8 0.71 0.67 0.65 0.66 0.68
(inter) 15/8 0.65 0.63 0.64 0.52 0.62
Deep	RF (intra) 14/6 0.73 0.63 0.58 0.71 0.72
(inter) 14/6 0.71 0.69 0.68 0.70 0.74
Mean	of	5	fasciae (intra) 0.76 0.63 0.60 0.72 0.72
(inter) 0.77 0.70 0.68 0.71 0.74
ICC: intraclass correlation coefficient, *(healthy/IIM) Figures in bold indicate ICC ≥ 0.70 ; VL = Vastus lateralis; 
RF = Rectus femoris
 
Figure 2 | Deltoid fascia thickness according to the 0.25 cm measurement protocol
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Exclusion of measurement due to less than 3 calliper pair placements occurred in 1 deltoid 
measurement, 1 VL deep measurement, 1 RF superficial measurement, and 4 RF deep 
measurements. One patient with refractory DM (patient 7, see Supplementary file Table 3) 
caused most the exclusions due to difficulty with assessing the fasciae and provided only 
measurements of the superficial VL fascia. The majority of measurements contained ≥ 
6 calliper pair of placements to determine fascia thickness (deltoid: 92%; VL superficial: 
100%, VL deep: 58%; RF superficial: 75%; and RF deep: 58%). 
The mean fascial thicknesses (SD) of the IIM group was: deltoid 1.15 mm (0.35), VL 
superficial fascia 1.36 mm (0.57), VL deep fascia 1.25 mm (0.14), RF superficial fascia 0.96 
mm (0.16), and RF deep fascia 1.29 mm (0.36) (Table 2). The deltoid fascia of IIM patients 
was more than 2 times thicker than healthy controls (Figure 2 and Table 2). This was most 
prominent when the mean of the 3 and 6 thickest measurement protocol was used (0.61 
vs. 1.34 mm (P < 0.001) and 0.57 vs. 1.25 mm (P < 0.001). 
Eleven of 12 IIM patients had increased deltoid fascia thickness, including 8 who had 
fascia thickness > 5 SD above normal. One patient had normal fascia thickness. She had a 
mild clinical presentation and had been in remission for over 5 years.
The superficial and deep fasciae of the VL and RF were not significantly thicker in IIM 
patients at a group level (Table 2). Two patients had thickening of the VL superficial fascia 
(+2.2 and +3.5 SD), 1 patient had thickening of the RF deep fascia (+2.7 SD), and 1 patient 
had thickening of the VL superficial fascia (+3.9 SD) and RF deep fascia (+4.1 SD). All 4 
patients had relevant thickening of the deltoid fascia, including 3 with markedly thickened 
fascia (> 5 SD). The patient with markedly thickened deltoid fascia and thickening of both 
the VL and RF fasciae suffered from acute untreated DM with classic symptoms (Gottron 
sign, muscle weakness, and periorbital edema). The other 3 patients (n = 1 DM and n = 2 
PM) were characterized by refractory IIM for which rituximab or high dose intravenous 
methylprednisolone were required. 
Fascia thickness in polymyositis and dermatomyositis
The fasciae thickness of the deltoid, VL, and RF were not significantly different between 
the subgroups of PM and DM patients. The 8 IIM patients with markedly increased deltoid 
fascia thickness consisted of 3 PM patients and 5 DM patients. 
Association between fascia thickness and other clinical parameters
We found no significant correlation between the clinical parameters, disease duration, 
serum CK, HAQ-DI score, muscle thickness, and fascia thickness of the deltoid among 
IIM patients. Nominal clinical parameters such as gender, ANA, anti-Jo1, subtype of IIM, 
clinical disease state, and presence of interstitial lung disease were not associated with 
relevant or markedly increased deltoid fascia thickness.
CHAPTER 6
92
Table 2 | Fascia thickness in mm of the different measurement protocols
Measurement protocol Healthy 
controls
IIM 
group
PM-
group
DM-
group
PM vs. DM
P-value
Deltoid Muscle
Based	on	0.25	cm	interval 0.54 
(0.08)
1.15 
(0.35)**
1.07 
(0.31)*
1.22 
(0.40)*
0.50
Based	on	3	thickest	measurements	 0.61 
(0.09)
1.34 
(0.36)**
1.31 
(0.36)*
1.35 
(0.38)*
0.87
Based	on	6	thickest	measurements 0.57 
(0.08)
1.25 
(0.33)**
1.21 
(0.32)*
1.29 
(0.37)*
0.68
VL superficial fascia
Based	on	0.25	cm	interval 1.28 
(0.30)
1.36 
(0.57)
1.14 
(0.21)
1.52 
(0.71)
0.22
Based	on	3	thickest	measurements 1.46 
(0.36)
1.56 
(0.65)
1.31 
(0.31)
1.73 
(0.79)
0.23
Based	on	6	thickest	measurements 1.38 
(0.34)
1.48 
(0.62)
1.25 
(0.27)
1.64 
(0.76)
0.24
VL deep fascia
Based	on	0.25	cm	interval 1.33 
(0.20)
1.25 
(0.14)
1.28 
(0.18)
1.23 
(0.12)
0.64
Based	on	3	thickest	measurements 1.43 
(0.23)
1.36 
(0.20)
1.42 
(0.22)
1.31 
(0.19)
0.40
Based	on	6	thickest	measurements 1.36 
(0.22)
1.29 
(0.17)
1.33 
(0.18)
1.26 
(0.16)
0.54
RF superficial fascia
Based	on	0.25	cm	interval 1.02 
(0.16)
0.96 
(0.16)
0.92 
(0.13)
0.99 
(0.19)
0.49
Based	on	3	thickest	measurement 1.15 
(0.18)
1.11 
(0.24)
1.06 
(0.18)
1.16 
(0.28)
0.52
Based	on	6	thickest	measurement 1.09 
(0.16)
1.04 
(0.20)
1.00 
(0.17)
1.08 
(0.24)
0.54
RF deep fascia
Based	on	0.25	cm	interval 1.23 
(0.17)
1.29 
(0.36)
1.32 
(0.28)
1.25 
(0.46)
0.80
Based	on	3	thickest	measurement 1.36 
(0.19)
1.41 
(0.36)
1.46 
(0.33)
1.37 
(0.43)
0.74
Based	on	6	thickest	measurement 1.30 
(0.18)
1.34 
(0.36)
1.38 
(0.33)
1.30 
(0.43)
0.77
Data presented in means (SD) in mm. * Significant increase compared to healthy controls (P<0.05). ** 
Significant increase compared to healthy controls (P<0.001); IIM: Idiopathic inflammatory myopathy; PM: 
Polymyositis; DM: Dermatomyositis
Discussion
In this study we showed that ultrasound is a reliable tool to measure fascia thickness of 3 
muscles (deltoid, vastus lateralis, and rectus femoris). Normal values of fascia thickness 
were established that can be used in clinical practice to evaluate patients with suspected 
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fasciitis. The deltoid fascia was thickened in almost all IIM patients, whereas in a minority 
of patients the fasciae of the VL and RF were also thickened compared to healthy controls.
In healthy controls the deltoid fascia was much thinner than the fascia of the quadriceps 
muscles. This can be explained by the fact that fascia can be distinguished into 2 different 
types: epimysial fascia and aponeurotic fascia (18). The deltoid fascia is classified as epimysial 
fascia, whereas the VL and RF fasciae are aponeurotic (18). Our results are in line with 
findings of human autopsy studies which demonstrated that epimysial fascia is thinner than 
aponeurotic fascia (20, 21). However, our ultrasound measurements seem to overestimate the 
thickness, particularly in the deltoid fascia, which was found to be 0.2 mm thick on autopsy 
studies, whereas the mean thickness on US was 0.5 mm. A potential explanation could 
be that the epimysial layer surrounding muscle fascicles cannot be distinguished from 
epimysial fascia, which adds up in the ultrasound fascia thickness measurement. 
In this study, we found a markedly increased deltoid fascia thickness in the IIM patient 
group compared to healthy persons, with significant results even in this small sample 
size. This shows that US can detect an accompanying fasciitis in these IIM. Although 
this diagnosis is not confirmed by MRI or biopsy, an increase of more than 5 SD in fascia 
thickness of the deltoid is suggestive of a fasciitis. These results correspond with previous 
studies which found structural aberrations of the fasciae in DM patients (5-9). A Japanese 
study with MRI and bloc muscle biopsies revealed the presence of fasciitis in 14 newly 
diagnosed DM patients (6). The majority of these MRIs and biopsies were carried out on 
proximal muscles of the arm (deltoid and biceps brachii). 
A novel finding of our study is that we also detected deltoid fascia thickening in PM 
patients. The Japanese study included 3 PM patients as controls, but found no signs of 
fasciitis on MRI or biopsy (6). From the reported results it was unclear which muscle fascia 
was assessed among the 3 PM controls. Our study results revealed no differences in fasciae 
thickness among PM and DM patients. 
To our surprise the clinically most affected muscle in IIM patients, i.e. the quadriceps (VL 
and RF), displayed no fascial thickening at a group level. However, US detected thickening 
of VL and RF fasciae in a small number of IIM patients. These patients were characterized 
by active ongoing inflammation (recent onset or refractory IIM). A possible explanation for 
the discrepancy between the thickened deltoid fascia and relative absence of thickened 
fasciae of VL and RF could lay in the anatomic difference between the epimysial deltoid 
fascia and the aponeurotic fasciae of the VL and the RF. The epimysial fascia is a much 
thinner collagenous layer which is tightly connected and not separable from the underlying 
epimysium (18, 20, 21). This contrasts with the aponeurotic fascia easily separates into layers (18). 
It is now being recognized that the deep fascia forms a complex structure with an important 
role in muscle contraction, tissue maintenance, and recovery (18). Skeletal muscles have 
fascial insertions which transmit muscle force to facilitate proper muscle contraction. 
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Furthermore, the aponeurotic fascia is rich in hyaluronan, which serves as a lubricant 
between the fascia and epimysium and is involved in tissue repair and regeneration (18, 
22). Structural deformation of the deep fascia could influence the biomechanics of the 
myofascial system and potentially contribute to complaints of muscle weakness or 
myalgia in patients with PM and DM. Therefore, future research should focus on the exact 
role of fascial involvement as part of the pathogenesis of PM and DM.
A limitation of this exploratory cross-sectional study is that fascia thickness was only 
measured by ultrasound. Muscle-fascia biopsy would have enabled histopathological 
analysis with fascia thickness measurement and possible detection of inflammatory 
cells in the fascia. Currently, fascial tissue is not collected in standard muscle biopsy 
procedures. Therefore, the diagnosis of an additional fasciitis might be missed among IIM 
patients. Furthermore, US measurement in our study was conducted on single location 
on the transverse plane of the muscle belly, while on visual evaluation it was apparent 
that the fascial thickening was not homogeneous, comparable to the patchy involvement 
of muscle tissue in this disease (1, 23). In addition, our analysis showed that the fascia US 
measurement protocol with selection of the 3 or 6 thickest measurements revealed the 
greatest differences between healthy controls and IIM patients. Therefore, a possibly 
better alternative US scan measurement protocol would consist of transverse fascia 
measurement along the full length of the muscle. This would increase the area of fascia 
scanned by US and would possibly increase detection of multifocal fascia involvement in 
IIM patients. However, this would also require that normal values of the fasciae of the 
different muscles be measured at several transverse planes along the full length of the 
muscle.
This study showed that the reliability of the fascia thickness measurement was sufficient 
for diagnostic purposes (ICC > 0.7). However, future studies are needed to determine if 
this reliability is sufficient to be able to use this technique in follow-up studies and to 
detect small changes over time. In this study a relatively low transducer frequency was 
used, especially in the patient group (10-5 MHz). One can hypothesize that the use of 
higher frequency transducers might increase the reliability, as the fascial layer is a rather 
thin structure and might make it possible to detect more subtle thickening. Furthermore, 
it would be interesting to perform echo-doppler measurements to detect possible 
hypervascularity of the tissue as sign of inflammation.
Conclusions
In conclusion, this study demonstrates that ultrasound is a reliable tool to measure fascia 
thickness of 3 proximal muscles (deltoid, vastus lateralis, and rectus femoris) among 
healthy persons and patient with IIM. We found that deltoid fascia thickness was increased 
significantly in patients with DM, as was previously described, and also in patients with 
PM. The quadriceps muscle, showed normal fascia thickness in most patients. Thickened 
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deltoid fascia is possibly indicative of a concomitant fasciitis and justifies future research 
to determine the diagnostic and prognostic value of this finding, and might further 
elucidate the pathogenesis of this muscle disease.
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Supplementary	file
Supplementary Table 3 | Ultrasound measurements of fascia thickness and muscle thickness of different muscles
Patient Deltoid
Fascia thick-
ness
(mm)
Deltoid
Muscle
thickness
(z-score)
VL	superficial
Fascia 
thickness
(mm)
VL deep
Fascia thick-
ness
(mm)
VL
Muscle
thickness
(z-score)
Rectus femoris
Fascia 
thickness
(mm)
Rectus femoris
Muscle
thickness
(z-score)
1 1.28 -2.8 1.42 1.35 -3.83 1.01 -2.06
2 1.00 -0.48 2.46 1.43 -0.75 1.28 0.24
3 1.26 -3.4 2.32 1.30 -0.88 1.04 NA
4 0.53 -2.5 0.96 NA -0.42 0.72 -0.70
5 0.75 -1.13 1.10 1.60 -2.06 0.84 -1.51
6 1.54 1.08 1.94 1.19 -0.84 1.06 -0.22
7 NA NA 1.26 1.20 -1.02 NA NA
8 0.49 -0.48 0.89 1.23 -0.75 0.84 0.24
9 0.69 0.16 1.25 1.30 -1.02 1.09 -1.55
10 0.64 -0.84 0.92 NA -0.74 1.01 0.08
11 1.34 -1.84 0.84 1.10 -1.81 0.80 NA
12 1.26 -0.56 1.08 1.20 -0.13 0.86 -3.26
VL: Vastus lateralis
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Quantitative muscle ultrasound: 
a potential tool for assessment 
of disease activity in juvenile 
dermatomyositis
K.J. Bhansing, E.P. Hoppenreijs, A.J. Janssen, A. van Royen-Kerkhof,  
M.W. Nijhuis-Van der Sanden, P.C.L.M. van Riel, S. Pillen
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Abstract
Objective To analyze whether there is a difference in echo intensity (EI) and muscle 
thickness of proximal and distal muscles in patients with juvenile dermatomyositis with 
high and low disease activity.
Methods A comparison of two groups: at diagnosis (n = 7) and clinical remission (n = 10). 
EI and muscle thickness of 4 muscles (left biceps, right forearm flexors, right quadriceps 
and left tibial anterior) were determined quantitatively. Muscle function was tested by 
handheld dynamometry and the CMAS.
Results There was a significant increased EI at high disease activity compared to low 
disease activity of the biceps (mean z-score 2.1 SD vs. 0.4 SD), forearm flexors (1.8 vs. 0) 
and tibialis anterior (2.5 vs. 0.9). The quadriceps showed a normal EI in both groups. At 
diagnosis muscle thickness of the proximal muscles was significantly decreased, whereas 
at clinical remission only the quadriceps was diminished. The EI significantly correlated at 
diagnosis to serum CK and CMAS (r = 0.58, p < 0.01) (r = -0.46, p = 0.024) and during clinical 
remission to the CMAS (r = -0.57, p < 0.01).
Conclusions These results imply that quantitative ultrasound, especially EI, possess the 
capacity to discriminate high and low disease activity in JDM. 
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Introduction
Juvenile dermatomyositis (JDM) is a disease characterized by inflammation of skeletal 
muscles and skin. Monitoring of disease activity in JDM is partly based on muscle enzymes. 
Nonetheless, muscle enzymes have limitations such as possible falls-negative results, 
poor correlations of serum CK levels with disease activity, muscle strength and physical 
function and only moderate responsiveness to clinical improvement (1). Therefore, there is 
need for additional tools to support evaluation of disease activity. 
Ultrasonography (US) is an objective and easily accessible tool to detect structural muscle 
changes caused by neuromuscular diseases. Its non-invasive nature makes it suitable for 
repeated measurements, especially in children (2). Affected muscles reveal a diminished 
muscle thickness and appear whiter (i.e. have an increased echo intensity) because of 
infiltration of fat, fibrous tissue or inflammation (3-7). Previous studies have shown that 
US can detect idiopathic inflammatory myopathies with high sensitivity (2, 8). However, it 
has not been investigated whether ultrasound can serve as monitor of disease activity. 
One of the important measurement properties of disease activity tool is its discriminative 
validation, which stands for the capacity to discriminate between the extremes of the 
spectrum, high and low disease activity (9, 10). Therefore, this study will serve to be a proof 
of principle to demonstrate the discriminative capacity of US as disease activity tool in 
JDM.
The aim of this study is to analyze whether there is a difference in echo intensity and 
muscle thickness of proximal and distal muscle groups in JDM patients with high and low 
disease activity.
Methods
Design
This is a cross-sectional study comparing a group of seven JDM patients with high disease 
activity, with ten patients with low disease activity. High disease activity is reflected by 
patients at diagnosis and low disease activity by patients in clinical remission, defined as 
no longer need to use immunosuppressive treatment.
Participants
Inclusion criteria were younger than 18 years of age and a diagnosis for JDM by a pediatric 
rheumatologist according to the Bohan and Peter criteria (11) (see Table 1). 
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Table 1 | Study population characteristics
Ultrasound measurement
Ultrasound measurements were performed with a Sonos 2000 (Hewlett-Packard, Andover, 
USA) with a 7.5 MHz transducer and a IU 22 (Philips, Best, The Netherland) with a linear 
broadband 17-5 MHz transducer. Muscle thickness and echo intensity (EI) of four different 
muscles (left biceps, right forearm flexors, right quadriceps femoris and left anterior 
tibial muscle) was determined as described in a previous study (12). EI was determined 
quantitatively using grey scale histogram analysis (12). A correction factor was applied to 
the measurements of the IU 22 device conform a previous published protocol to make the 
EI measurements of both devices comparable (13). The ventral side of all extremities was 
screened for subcutaneous or intramuscular calcifications. 
Muscle function
Maximum voluntary isometric contraction of all muscles was assessed with a handheld 
dynamometer (Microfet 2, Almere, The Netherlands) using the ‘break’ method (14). 
Furthermore, the childhood myositis assessment scale (CMAS) was applied to all 
participants (15). 
Characteristics No. At diagnosis
(n	=	7)
No. Clinical remission
(n	=	10)
Age (years) 7 4.1 (1.4 - 12.3) 10 14.4   (4.2 - 16.1)
Sex	(boys/girls) 7 2/5 10 5/5
Time	from	diagnosis	(years) - - 10 8     (1 - 11.3)
Muscle parameters
Muscle	biopsy
-	Infiltrates
- MHC-I staining
-	Perifascular	atrophy
- MAC-staining
7
6	(86%)
6	(86%)
4	(57%)
4	(57%)
NA
CMAS 5 22  (6 - 40) 10 49 (15 - 52)
Strength	Biceps	brachii	(z-score) 2 -3.8 (-5.1; -2.5) 9 -1.0 (-2.8- -0.5)
Strength	Forearm	Flexors	(z-score) 0 - 9 -1.3 (-4.6- 0.7)
Strength	Quadriceps	(z-score) 2 -3.4 (-4.5; -2.3) 9 -0.4 (-4.0- 1.8)
Strength	Tibialis	anterior	(z-score) 0 - 7 0.2 (-1.3- 1.9)
Serum	CK	(U/L) 7 396 (91 - 7149) 3 70 (65 - 204)
Data is presented in medians (range). No. = number of patients; NA = not applicable ; CMAS = Childhood myositis 
assessment scale; CK = Creatine kinase
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Statistical analysis
All US measurements were compared to our database of normal values comprising 59 
healthy children aged 11 weeks to 16 years of age, described in a previous study (12). EI is 
independent of age and body composition in children. As muscle thickness has shown to 
be dependent on weight, all values were corrected for weight and expressed as z-scores 
(i.e. the number of standard deviations above or below normal). CMAS and z-scores of 
ultrasound parameters (muscle thickness and EI) were compared between both groups 
with the independent samples t-test and Mann-Whitney U test, comparisons with 
normal values were performed with one-sample t-test. Ultrasonography abnormalities 
(defined as muscle thickness < -2 SD (atrophy) and increased EI > 2 SD) were compared 
with the Chi-square test. Correlations between ultrasound parameters, CMAS, serum CK 
measurements were determined by Pearson’s analysis. Statistical significance was defined 
as p-value ≤ 0.05. 
Results
Muscle force and CMAS
Muscle force measurements at diagnosis (n = 2) revealed muscle weakness of the proximal 
muscles. The other five children were unable to perform measurements due to their young 
age, non-compliance or pain. 
In the group at clinical remission eight patients showed normal or only slightly diminished 
force on dynamometry. Two patients endured muscle weakness. One of these patients had 
calcifications predominantly surrounding the hip, affecting her mobility. The other patient 
had extensive calcifications surrounding the shoulders, elbow, hip and knee and several 
muscles and was therefore wheelchair bound.
CMAS scores (maximum score 52) showed a significant difference between the groups 
at diagnosis (median 22, range 6 – 40) and during clinical remission (median 49, range 
15 - 52). In remission phase the CMAS was normal in seven patients, three patients had a 
decreased CMAS score of whom two patients that suffered from calcifications. 
Echo intensity 
At diagnosis the group EI was significantly increased in all muscles except the quadriceps, 
and significantly higher than the patients at clinical remission (Figure 1A and Table 2). 
The highest EIs were seen in the tibialis anterior muscle. An increased EI (EI > 2 SD) was 
observed in five out seven patients at diagnosis (71%); in more than 2 muscles (n = 2), in 2 
muscles (n = 1) and in 1 muscles (n = 2). The remaining two patients showed a borderline 
abnormal EI (1.5 < EI ≤ 2) in one or two proximal muscles. 
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Table 2 | Muscle ultrasound findings
Figure 1 | Echointensity (A) and Muscle thickness (B) at diagnosis and clinical remission
At clinical remission EI of all muscles was not increased at a group level, although four 
patients had a muscle EI > 2 SD in one or more muscles. These four patients scored the 
lowest on the CMAS in the clinical remission group and two patients suffered from severe 
atrophy and calcifications.  
Ultrasound parameters No. At diagnosis
(n	=	7)
No. Clinical remission
(n	=	10)
Significance
(p-value)
Echointensity (z-score)
Biceps	brachii	left 7 2.1 (1.8)† 10 0.4 (0.9) 0.03*
Forearm	flexor	right 7 1.8 (1.9)† 10 0 (1.2) 0.03*
Quadriceps	right 7 1.3 (2.4) 10 0.3 (1.3) 0.318 
Tibialis	anterior	left 7 2.5 (1.4)† 10 0.9 (1.6) 0.04*
Total	of	muscles	with	z-score	>2 28 11 40 5 0.02*
Total	of	patients	with	muscles	z-score	>2 7 5 10 4 -
Intramuscular	calcifications	(n) 7 0 10 2 -
Muscle Thickness (z-score)
Biceps	brachii	left 7 -1.4 (1.4)† 10 -0.8 (1.2) 0.31
Forearm	flexor	right 7 0.2 (1.3) 10 0.1 (1.8) 0.99
Quadriceps	right 7 -1.4 (1.4)† 9 -1.0 (1.0)† 0.53
Tibialis	anterior	left 7 0 (0.7) 10 -0.3 (1.1) 0.50
Total	of	muscles	with	z-score	<-2 28 6 39 4 0.30
Data presented in mean (SD) No. = number of patients/muscles)
*statistical significant difference between groups at diagnosis and clinical remission
†statistical significant difference from healthy persons
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Muscle Thickness 
At diagnosis muscle thickness of the proximal muscles was significantly decreased. 
Decreased muscle thickness of < -2 SD was seen in four patients (of two muscles in two 
patients and of one muscle in the other two patients). At clinical remission, muscle 
thickness was only decreased in the quadriceps while all other muscles were normal. (Fig. 
1B and table 2.) Only one patient showed severe atrophy (3 muscles with muscle thickness 
< -2) due to extensive calcifications. 
Correlations between CMAS, serum CK and ultrasound
The patient with severe calcifications in the group at clinical remission was regarded to 
be an outlier and therefore excluded from this analysis. In both groups at diagnosis and 
during clinical remission the CMAS was inversely correlated to EI of all muscles (r = -0.46, p 
= 0.024; r = -0.57, p < 0.01). The CMAS was also significantly correlated to muscle thickness 
but only in the group after treatment (r = 0.46, p = < 0.01). The serum CK of patients at 
diagnosis was significantly correlated with EI of all muscles (r = 0.58, p < 0.01). 
Discussion
This is the first study that investigated the discriminative capacity of quantitative muscle 
US as disease activity tool in JDM. Muscle EI of biceps, forearm flexors and tibialis anterior 
was significantly higher at diagnosis compared to clinical remission. This implies that EI 
possesses the capacity to discriminate between high and low disease activity in JDM. 
Muscle thickness was less discriminative: decreased muscle thickness was found only in 
the proximal muscles at diagnosis, with the quadriceps still being slightly diminished in 
the patients measured at clinical remission, leading to no significant difference between 
both groups. Therefore, it seems that muscle thickness measurement is less well suited as 
ultrasound parameter for monitoring disease activity. 
Increased EI has shown to be caused by increased amount of intramuscular fibrosis 
and fatty tissue (3, 4). However, in early states of JDM only little fibrosis is present, which 
implies that inflammation itself causes increased EI. Its known from several human and 
animal studies that increased muscle EI can be related to an inflammatory response (5-
7). In the light of this study, the normalization of EI at clinical remission implies that the 
inflammation has resolved and no residual damage (i.e. fibrosis) is present. However, three 
patients at clinical remission showed an slight to severe increased EI. This increased EI 
was accompanied with the lowest CMAS scores and therefore indicated the presence of 
residual muscle damage after JDM.
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Surprisingly, the clinically most affected muscle, the quadriceps, showed the least increase 
of EI at diagnosis. It remains unclear why the quadriceps muscle did not show the same or 
even more EI changes. 
A significant correlation was found between EI and CMAS. This illustrates that US might 
be a good tool to evaluate the severity of muscle changes. 
MRI has also been studied as monitoring tool in JDM (16). A standardized MRI scoring 
system has been proposed that showed acceptable reliability for assessing disease activity 
in JDM (16). However, the main disadvantages of MRI are its cost, availability and need of 
sedation in young children, whereas ultrasound can be done at bedside within 15 minutes 
and without sedation. 
Conclusions
In conclusion, this study serves as proof of principle that quantitative US has the important 
capacity to discriminate high and low disease activity in JDM. The next step would be to 
assess its responsiveness by means of a prospective study with other monitoring tools 
such as biochemical markers, CMAS, and muscle MRI and to identify its optimal place in 
the follow-up of JDM. 
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CHAPTER 8
Summary and general discussion
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The main objectives of these thesis was to study the clinical aspects and outcome of 
patients with idiopathic inflammatory myopathies (Part I) and the diagnostic properties of 
Quantitative Muscle UltraSound (QMUS) in these patients (Part II). 
Part I Clinical aspects
Chapter 2 describes a study in which different types of pulmonary hypertension (PH) 
were identified in patients with idiopathic inflammatory myopathy (IIM). PH is a life-
threatening condition presenting with symptoms as breathlessness, fatigue and syncope. 
Recent cohort studies revealed a worsened prognosis of patient with IIM and PH. 
Interstitial lung disease (ILD) is frequently found among IIM patients, occurring in up to 
65% of the patients. ILD is a possible cause of PH among patients with IIM. Surprisingly we 
found that a relevant group (33%) of IIM patients suffered from non ILD-PH, which reflects 
the presence of a pulmonary arterial hypertension (PAH) phenotype. These patients could 
possibly benefit from vasoactive therapy. Therefore, we also described retrospectively the 
outcome of vasoactive therapy during an observed median follow-up of 16 months and 
observed a decreased progression. However, the role of vasoactive therapy remains to be 
defined in patient with IIM suffering from PAH or PH-ILD. 
In Chapter 3, we assessed the clinical and myopathological features of patients with SSc-
PM overlap. The prevalence of myopathies in patients with systemic sclerosis (SSc) varies 
from 5% to 81%, depending on the use of different definitions of muscle involvement 
(1-6). Myositis in SSc patients resembles clinical and biologic features of patients with 
polymyositis (PM). A three-way comparison of patients with SSc-PM overlap to patients 
with SSc and PM on clinical features, muscle biopsy features and causes of death was 
made. We found adverse outcome in the SSc-PM overlap patients with a mortality of 32%, 
of which half was related to cardiac diseases. Furthermore, the prevalence of pulmonary 
fibrosis was significantly higher in SSc-PM (83%) compared to SSc (49%) and PM (53%). 
SSc or myositis specific antibodies were nearly absent in SSc-PM group. In muscle biopsies 
of SSc-PM patients necrotic muscle fibers were present in 96% compared to 67% of the 
PM patients). 
Chapter 4 reports on the mortality of patients with SSc-PM overlap compared to patient 
with SSc without myositis. Data from the Nijmegen Systemic Sclerosis cohort were used. 
The 5- and 10-year cumulative survival from diagnosis were 82% and 68% for the SSc-PM 
group and 93% and 87% of the SSc group. Multivariate survival analysis, adjusted for age at 
diagnosis, modified Rodnan skin score, diffuse cutaneous subtype and male sex, revealed 
a worse survival for patients with SSc-PM overlap compared to patients with SSc. The 
most common cause of death among patient with SSc-PM overlap was cardiopulmonary 
involvement (63%), which was similar to the patients with SSc (51%). 
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Part II Muscle ultrasound
In Chapter	5, results of our muscle ultrasound study are described in which the diagnostic 
accuracy of QMUS was assessed in patients suspected for IIM. In addition, results were 
compared to electromyography (EMG). In 57 patients, suspected for IIM, panel diagnosis 
blinded for QMUS was used as reference standard. QMUS results were used to classify 
patients according an ultrasound neuromuscular disorder (NMD) algorithm (normal/
borderline/abnormal).Twenty-two patients (39%) were diagnosed with IIM; 8 PM, 4 
DM, 4 necrotizing myopathy, 3 inclusion body myositis and 3 non-specific myositis. 
Furthermore, we found an increased echointensity of the sternocleidomastoid, biceps, 
forearm flexor and tibialis anterior in the IIM group. In our study, we conclude that QMUS 
with neuromuscular algorithm provides a similar diagnostic accuracy compared to EMG 
for patients suspected of an IIM. Therefore, QMUS could serve as non-invasive alternative 
for EMG if no disorders of the nervous system are expected.
In the previous muscle ultrasound study we observed frequently a thickened fascia 
of muscle among patient with IIM. This serendipity was reason for us to systematically 
assess fascia of patients with IIM and to compare this with healthy controls. Chapter	6 
provides the results of a muscle ultrasound in which we investigated the reliability of 
fascia thickness measurements. In addition, we cross-sectionally analyzed whether a 
concomitant fasciitis could be detected in patients with DM or PM. A reliable protocol 
for measuring fascia thickness was established for the deltoid, vastus lateralis and rectus 
femoris muscle among 54 healthy persons. Fascia thickness measurement among seven 
patients with DM and five patients with PM showed that the deltoid fascia thickness 
was twice as thick in the group of DM/PM compared to healthy controls. Eight patients 
revealed strongly thickened deltoid fascia (> 5 SD). Four patients also had a mild fasciae 
thickening of the vastus lateralis and/or rectus femoris. These study results provide 
evidence that fasciitis is involved in the pathogenesis of DM and to lesser extent in PM. 
The objective of the study described in Chapter 7 was to evaluate the role of QMUS in the 
follow-up of children with juvenile dermatomyositis (JDM). A cross-sectional comparison 
regarding ultrasound muscle thickness, echo-intensity (EI) and muscle function was 
performed in two groups of patients with JDM: at diagnosis (n = 8) and in clinical remission 
(n = 10). At diagnosis muscle thickness of the proximal muscles (biceps brachii, quadriceps 
femoris) were significantly decreased and muscle echo intensity was significantly increased 
in the biceps brachii, forearm flexors and anterior tibial muscle. Muscle EI was abnormal 
in 5 out of 7 patients (71%). During clinical remission, muscle thickness and muscle EI had 
normalized in all muscles except the quadriceps for muscle thickness. Two patients showed 
an abnormal ultrasound exam with extensive calcifications. The Childhood Myositis 
Assessment Scale, a marker of muscle function, correlated significantly inversely to muscle 
EI of all muscles at diagnosis and during clinical remission. Surprisingly, the clinically most 
affected muscle, the quadriceps, showed the least increase of EI at diagnosis. A possible 
explanation could be that edema or an increased blood flow decreased muscle EI. 
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These promising results indicate that QMUS is capable to discriminate between high and 
low disease activity in juvenile dermatomyositis. Furthermore, muscle EI correlates with 
muscle function. Residual muscle damage can also be visualized. 
General conclusions of the present thesis
–  Complaints of dyspnea among patient with IIM can be related to PAH and not only 
ILD or deconditioning due to IIM itself. The role of vasoactive therapy remains to be 
defined in patient with IIM suffering from PAH.
–  Patients with SSc-PM have an increased prevalence of pulmonary fibrosis and cardiac 
disease as causes of death compared to patients with SSc and PM. Muscle biopsies 
show necrotizing muscle fibers with inflammation as hallmark of SSc-PM overlap.
–  Patients with SSc-PM overlap have a worse survival compared to patients with SSc. 
–  QMUS with neuromuscular algorithm provides a similar diagnostic accuracy compared 
to EMG for patients suspected of an IIM. Therefore, QMUS could serve as a potential 
non-invasive screening tool for clinicians to detect possible myopathies and to rule out 
the presence of IIM.
–  QMUS could serve as non-invasive tool for detecting of a concomitant fasciitis in 
patients with DM or PM.
–  QMUS echo-intensity has the capacity to discriminate between high and low disease 
activity in patients with juvenile dermatomyositis. In addition, muscle EI correlates 
with muscle function. 
General Discussion
Part I Clinical aspects
The Nijmegen Myositis cohort revealed that possible pulmonary hypertension on cardiac 
ultrasound was present among our patients. We surprisingly found that a relevant group of 
these IIM patients suffered from pulmonary arterial hypertension (PAH). The coincidence 
of PAH with IIM is rare compared to other connective tissue such as systemic sclerosis 
(7). I do not recommend general screening for all patients with IIM for presence of PAH. 
However, in case of progressive dyspnea, syncope or right heart failure which cannot be 
explained by ILD or respiratory muscle inflammation, screening for PAH is recommended. 
Treating physicians of patients with IIM should be aware of the possible presence of PAH. 
Research in IIM regarding PAH is lacking to date. In registration studies of vasoactive 
medication patients with IIM are not included. New insights in the pathogenesis of PAH 
reveal that both pulmonary vascular remodeling and inflammation are key pathological 
abnormalities. Therefore, I believe that combination of vasoactive therapy with 
immunosuppressive agents could change the scope of therapy in these patients. Currently, 
rituximab (chimeric anti-human CD20) is assessed in patients with systemic sclerosis and 
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PAH (ClinicalTrials.gov identifier NCT01086540) and tocilizumab (humanised anti-IL-6 
receptor antibody) (ClinicalTrials.gov identifier NCT02676947) in patients with PAH. 
Patients with overlap myositis are also included in our myositis cohort. The majority of 
the overlap patients had a systemic sclerosis polymyositis overlap (SSc-PM overlap). In 
our studies with SSc-PM overlap we found a increased prevalence of necrotic muscle 
fibers with inflammation in muscle biopsies (8). Therefore, I recommend that SSc-PM 
overlap should be included in the differential diagnosis when muscle biopsy findings show 
necrotic muscle fibers with inflammation. Furthermore, we observed increased mortality 
and presence of interstitial lung disease compared to patients with systemic sclerosis 
(9). Regarding the mortality, cardiac disease as cause of death was more often observed 
among SSc-PM patients. Therefore, I belief that SSc-PM overlap reflects a more aggressive 
disease with a poor prognosis. This should warrant treating physicians to perform regular 
screening for cardiopulmonary complication and timely initiation of therapy. In addition, 
clinical trials conducted with existing DMARDs , but also new emerging treatment options 
such as the biologicals are necessary to determine the appropriate treatment strategy.
Part II Muscle ultrasound
The clinical diagnosis of IIM is based on the clinical presentation, elevation of creatine 
kinase (CK), serology together with electromyography (EMG) and muscle biopsy (10). 
However, EMG findings are not disease specific and are partly performed to rule out a 
neurogenic cause (11). Muscle biopsy with histopathological evaluation by experienced 
neuromuscular pathologist is central to diagnostic workup (10, 12-15) False negative muscle 
biopsies by sampling error have been reported (12, 16-18). For these reasons muscle imaging 
has been suggested to be included in the diagnostic work up (19). Quantitative muscle 
ultrasound (QMUS) imaging has proven to be a useful, non-invasive technique to visualize 
pathological skeletal muscle tissue among patients with IIM (20-27). Result of our diagnostic 
ultrasound study provides evidence that QMUS has similar diagnostic value compared 
to EMG for patients suspected of an IIM. The combination of QMUS and EMG did not 
lead to significant improvement of diagnostic accuracy. QMUS is limited in the ability 
to properly differentiate between inflammatory myopathies and other myopathies. The 
strength of QMUS lays in the ability to differentiate between healthy muscle tissue and 
affected muscles. Therefore, I believe that QMUS could serve as a potential screening tool 
for clinicians to detect possible myopathies and to rule out the presence of IIM. Moreover, 
QMUS could be a non-invasive alternative for EMG if no disorders of the nervous system 
are expected. 
Power Doppler (PD) ultrasound measurements are used to detect changes of blood 
perfusion in the human tissue (28). In daily clinic practise, rheumatologists often use 
PD ultrasound measurements to assess the degree of inflammation among patients 
suffering from arthritis. Therefore, PD ultrasound measurement could potentially 
improve diagnostic accuracy of muscle ultrasound since inflammation of the muscle is 
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one the hallmarks of IIM. Semi-quantitative grading system for synovial PD ultrasound 
are widely used in ultrasound studies and clinic practise for patients with rheumatoid 
arthritis (29). These grading systems provide a possible blue print how we could incorporate 
PD measurement to our current QMUS measurements. Altogether, this warrants for 
diagnostic muscle ultrasound study with QMUS and PD measurement in patients 
suspected of IIM.  
An example of serendipity occurred during ultrasound measurements of our patients of 
the myositis cohort. The patients were consecutively recruited as a part of an ongoing 
study to determine the value of muscle ultrasound as disease activity tool. We observed an 
increased deltoid fascia among a group of DM and PM patients. This shows that ultrasound 
is capable of detecting an accompanying fasciitis in these IIM. Although, this diagnosis is 
not confirmed by MRI or biopsy, an increase of more than 5 SD in fascia thickness of the 
deltoid is very suggestive for a fasciitis. The results of this study correspond with previous 
studies who found structural aberrations of the fasciae in DM patients (30-34). A Japanese 
study with MRI and bloc muscle biopsies revealed fasciitis being present in 14 newly 
diagnosed DM patients (31). I believe that fasciitis could reflect (sub)clinical disease activity 
of the IIM in analogue with tenosynovitis in patients with rheumatoid arthritis. Another 
potential explanation could be that fascia involvement reflects damage of previous 
inflammation such as joint erosions in patients with rheumatoid arthritis. Therefore, 
the clinical implication of this finding remains unclear. A prospective ultrasound study is 
warranted to assess the fascia during diagnosis and follow-up together with assessment of 
disease activity and biopsy of affected fascia. Thus, we conclude that a thickened deltoid 
fascia is indicative of a collateral fasciitis and justifies future research to determine the 
diagnostic and prognostic value of this finding in order to elucidate the pathogenesis of 
fascia involvement in this muscle disease.
In daily clinical practice mainly serum CK, clinical symptoms, manual muscle testing (MMT) 
and EMG are used to monitor disease activity. Disease activity can be defined as reversible 
inflammatory manifestation of IIM which varies from mild to severe (35). However, serum 
CK, MMT and EMG findings do not always correlate with increase of disease activity. In 
addition, imaging modalities might be useful in the outcome assessment of patients with 
IIM. In our ultrasound study among patients with juvenile dermatomyositis, we found that 
QMUS is capable to discriminate between high and low disease activity. Furthermore, 
muscle EI correlated with muscle function. Residual muscle damage can also be visualized. 
This proof of concept study indicates that QMUS has a potential as monitoring tool. The 
next step would be to perform a prospective study to evaluate the responsiveness of 
muscle ultrasound as a disease activity monitoring tool. In addition, QMUS measurement 
should be extended with PD measurement to improve detecting of inflammation. 
CHAPTER 8 
118
Conclusion
This thesis aimed to contribute to the knowledge regarding the clinical aspects and 
outcome of patients with IIM (Part I) and the diagnostic properties of QMUS in these 
patients (Part II). In Part I we focused on PH and patients with SSc-PM overlap. We 
recommend treating physicians to consider the presence of PAH in case of unexplained 
dyspnea even in the presence of limited ILD. I do not recommend to screen all patients 
with IIM, because the prevalence of PAH is rare among patients with IIM. Patients with 
SSc-PM overlap have a worse survival, probably reflecting more active disease which 
explains the increased prevalence of pulmonary fibrosis and cardiac disease as causes of 
death compared to patients with SSc and PM. Muscle biopsies show necrotizing muscle 
fibers with inflammation as hallmark of SSc-PM overlap. Therefore, early detection and 
timely start of immunosuppressive therapy in patients with SSc and IIM overlap could be 
important.
In Part II, we conclude that QMUS could serve as a potential non-invasive screening tool for 
clinicians to detect possible myopathies and to rule out the presence of IIM. Furthermore, 
QMUS could serve as non-invasive tool for detecting of a concomitant fasciitis in patients 
with DM or PM. The clinical implication of fascia involvement needs further investigation. 
QMUS echo-intensity has the capacity to discriminate between high and low disease 
activity in patients with juvenile dermatomyositis. A prospective study is warranted to 
properly assess the responsiveness of QMUS and its value as monitoring tool.
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Idiopathische inflammatoïre myopathiën (IIM) (ook myositis genoemd) zijn ziektes die 
zich kenmerken door chronische ontsteking van de spieren. Daarbij zijn het reumatische 
systeemziekten, omdat de ontsteking ook kan zitten in andere organen zoals longen, 
gewrichten, huid, maagdarm kanaal of het hart. Er bestaan verschillende vormen van 
myositis, namelijk polymyositis (PM), dermatomyositis (DM), inclusion body myositis 
(IBM), niet specifieke myositis (NSM) en immuun gemedieerde necrotiserende myopathie 
(IMNM). De exacte onderliggende oorzaak voor deze ziektebeelden blijft onduidelijk. 
Het is wel duidelijk dat het om auto-immuun ziekten gaat gezien de aanwezigheid van 
ontstekingscellen in spierbiopten en het goede effect op immunosuppressiva.  
De 2 hoofddoelstellingen van dit proefschrift zijn: het onderzoeken van de klinische 
aspecten en uitkomsten bij patiënten met idiopathische inflammatoïre myopathiën (Deel 
1) en het onderzoeken van de diagnostische waarde van kwantitatieve spierechografie bij 
deze patiënten. (Deel 2) 
Deel 1 Klinische aspecten 
Hoofdstuk 2 bevat een studie, waarbij er is gekeken naar de verschillende vormen 
van pulmonale hypertensie bij patiënten met IIM. Pulmonale hypertensie (PH) is een 
levensbedreigende complicatie waarbij patiënten last hebben van kortademigheid, 
vermoeidheid en/of flauwvallen. Interstitieel longaandoening (ILD) komt frequent (tot 
65%) voor bij patiënten met IIM en is één van de mogelijke oorzaken voor PH. Verrassend 
genoeg vonden wij dat een relevante groep (33%) van de patiënten met IIM leden aan 
een niet door ILD veroorzaakte PH. Waarschijnlijk werd dit veroorzaakt door pulmonale 
arteriële hypertensie (PAH). Deze patiënten zouden kunnen profiteren van behandeling 
met vasoactieve medicatie. Bij het analyseren van de middellange termijn uitkomsten op 
vasoactieve medicatie zien we een trend van vertraagde verslechtering. Wat de precieze 
rol van vasoactieve behandeling wordt voor patiënten met IIM en PAH of PH als gevolg 
van ILD zal zich nog moeten uitkristalliseren in de toekomst. 
In Hoofdstuk 3 beschrijven we de klinische aspecten en histologische bevindingen van 
spierbiopten bij patiënten met zowel systemische sclerose (SSc) als ook polymyositis 
(SSc-PM). De prevalentie van myopathie bij patiënten met systemische sclerose varieert 
van 5% tot 81% en is afhankelijk van de gekozen definitie voor spier betrokkenheid. 
De myositis bij patiënten met SSc-PM vertoont veel klinische overeenkomsten met 
patiënten die lijden aan PM. In deze studie is er vergelijking gemaakt tussen 3 groepen 
van patiënten, namelijk SSc-PM vs. SSc vs. PM. We vonden een verhoogde mortaliteit 
van 32% binnen de groep van SSc-PM patiënten, waarvan de helft was gerelateerd 
aan cardiale oorzaken. Verder vonden we een verhoogde prevalentie van ILD (83%) in 
vergelijking tot SSc (49%) en PM (53%). SSc of myositis specifieke antistoffen kwamen 
nagenoeg niet voor in de SSc-PM groep. Opvallend genoeg werd er bij bijna iedereen 
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necrotiserende spiervezels gezien (96%) in de SSc-PM groep in vergelijking tot 67% in de 
PM groep. 
Hoofdstuk 4 gaat verder in op de mortaliteit van patiënten met SSc-PM in vergelijking 
tot patiënten met SSc. De 5 en 10 jaar cumulative overleving vanaf diagnose was 82% en 
68% voor de SSc-PM groep in vergelijking tot 93% en 87% voor SSc groep. Multivariate 
overleving analyse, gecorrigeerd voor leeftijd bij diagnose, de Rodnan huidscore, subtype 
diffuse of gelimiteerde SSc en geslacht, liet een slechtere overleving zien voor patiënten 
met SSc-PM ten opzichte van SSc patiënten. De meest voorkomende oorzaak van sterfte 
was cardiopulmonale betrokkenheid (63%).  
Deel 2 Spierechografie  
In Hoofdstuk	5 beschreven we de resultaten van onze spierechografie studie, waarbij we 
hebben gekeken naar de diagnostische waarde van echo bij patiënten met een verdenking 
op IIM. De studie populatie bestond uit 57 patiënten, waarbij een panel van experts als 
gouden standaard de diagnose wel of geen IIM heeft gesteld. Daarbij waren de experts van 
het panel geblindeerd voor de uitslag van de spierechografie.   
Kwantitatieve spierechografie gaf volgens een al bekend neuromusculaire algoritme 
3 uitslagen, namelijk normaal, mogelijk afwijkend of afwijkend. In de studie werden 22 
patiënten (39%) gediagnosticeerd met IIM op basis van de panel diagnose; 8 PM, 4 DM, 
4 IMNM, 3 IBM and 3 NSM. Verder vonden we een verhoogde echo intensiteit van de 
sternocleidomastoïdeus, biceps brachii, onderarm flexoren en tibialis anterior in de IIM 
groep. We vonden dat kwantitatieve spierechografie met gebruik van neuromusculaire 
algoritme een vergelijkbare diagnostische waarde heeft als EMG. Daarom zou 
kwantitatieve spierechografie als een niet invasieve alternatief kunnen dienen voor EMG 
als er geen verdenking is op een aandoening van zenuwstelsel.    
In de voorgaande spierechografie studie observeerde we een verdikking van de fascie van 
de spieren. Deze toevalsbevinding was voor ons aanleiding om systematisch de fascie bij 
patiënten met IIM te onderzoeken en te vergelijken met gezonden personen. Hoofdstuk 
6 bevat de resultaten van de echometingen van de fascie. Daarbij hebben we een fascie 
echo meetprotocol ontwikkeld met voldoende betrouwbaarheid voor het meten van de 
deltoïdus, vastus lateralis en rectus femoris bij 54 gezonden personen. Met gebruik van 
dit meetprotocol vergeleken wij cross-sectioneel patiënten met DM (n = 7) of PM (n = 5) 
met gezonden vrijwilligers. De fascie dikte van de deltoïdus was 2x zo dik bij de groep 
van DM/PM in vergelijking met gezonde vrijwilligers. Acht patiënten hadden een sterk 
verdikte fascie van de deltoïdus (> 5 SD). Vier patiënten had ook een milde verdikking van 
de fascie van de vastus lateralis en/of rectus femoris. Deze studie resultaten geven een 
nieuw inzicht dat fasciitis mogelijk een rol speelt in de pathogenese van DM en in mindere 
mate bij PM. 
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Het doel van de studie beschreven in Hoofdstuk 7 was om discriminatieve validiteit van 
kwantitatieve spierechografie te evalueren bij kinderen met juveniele dermatomyositis 
(JDM), met andere woorden het vermogen om onderscheid te maken tussen hoge en 
lage ziekteactiviteit. We verrichten een cross-sectionele studie met vergelijking tussen 2 
groepen bij diagnose (n = 8) en klinische remissie (n = 10). Daarbij werd een kwantitatieve 
spierechografie meting verricht (spierdikte en echointensiteit), spierfunctie en serum CK 
waardes bepaald. Bij diagnose was de spierdikte van de proximale spieren (biceps brachii 
en quadriceps femoris) significant verlaagd en was de echointensiteit significant verhoogd 
van de biceps brachii, onderarm flexoren en de tibialis anterior.
Bij klinische remissie was de spierdikte en echointensiteit normaal, behalve voor de 
spierdikte van de quadriceps. Bij 2 patiënten vonden we uitgebreide calcificaties met 
behulp van de echo. De spierfunctie correleerde significant met de echointensiteit van 
de spieren bij diagnose en klinische remissie. Opvallend genoeg liet de klinisch meest 
aangedane spier, de quadricpes, de minst verhoogde echointensiteit zien bij diagnose. 
Een mogelijk verklaring hiervoor is dat oedeem of een verhoogd bloed toevoer door 
inflammatie een effect heeft gehad op de echointensiteit. 
Deze veelbelovende resultaten laten zien dat kwantitatieve spierechografie in staat is om 
hoge en lage ziekteactiviteit bij JDM te onderscheiden. Verder correleert echointensiteit 
van de spieren met de spierfunctie en kan er met spierechografie ook schade aan spieren 
worden gevisualiseerd.
Algemene conclusies van dit proefschrift
–  Kortademigheid bij patiënten met IIM kan ook het gevolg zijn van PAH en niet alleen 
door ILD of deconditionering bij het ziektebeeld IIM. De rol van vasoactieve behandeling 
bij patiënten met PAH en IIM zal zich nog moeten uitkristalliseren in de toekomst. 
–  Patiënten met SSc-PM hebben een verhoogd voorkomen van ILD en cardiale oorzaken 
als sterfte in vergelijking tot patiënten met SSc of PM. Spierbiopten laten zien dat de 
aanwezigheid van necrotiserende spiervezels met inflammatie een typerend kenmerk 
zijn. 
–  Patiënten met SSc-PM overlap hebben een slechtere overleving in vergelijking met 
patiënten met SSc. 
–  Kwantitatieve spierechografie met neuromusculaire algoritme heeft een vergelijkbare 
diagnostische waarde als EMG bij een verdenking op IIM. Daarom zou kwantitatieve 
spierechografie als non-invasieve alternatief voor EMG kunnen dienen bij screening bij 
verdenking myopathie en/of uitsluiten van de aanwezigheid van IIM.  
–  Kwantitatieve spierechografie zou als non invasieve screening kunnen worden ingezet 
voor het detecteren van tegelijkertijd voorkomende fasciitis bij patiënten met DM of PM.
–  Kwantitatieve spierechografie heeft de capaciteit om een onderscheid te maken tussen 
hoge en lage ziekteactiviteit bij kinderen met JDM. Daarbij correleert echointensiteit 
van de spieren met de spierfunctie.   
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De wetenschap heeft mij veel gebracht. Ik heb mij verdiept in 
onderwerpen waar ik geen weet van had, ik heb samen gewerkt 
met vele collega’s, ik heb geleerd om te gaan met tegenslagen en 
deadlines. Ik heb me verwonderd over bevindingen. De reis was 
enerverend, uitdagend, tegelijkertijd ook vermoeiend en elke dag 
weer anders. Een soortgelijke ervaring deel ik samen met Andjenie 
over de vele reizen die we hebben gemaakt. We koesteren daaraan 
vele goede herinneringen, waarvan een aantal hoogtepunten terug 
te vinden zijn in dit boekje. Het oneindige van de wetenschap…het 
oneindige van zand in de woestijn en het oneindige van de liefde.
“Door wetenschap bereikt men veel, 
doch slechts de liefde voort tot volmaaktheid”
Rabindranath Tagore 1861-1941, dichter en 1e Indiase Nobelprijs winnaar
